MEDICAL PROPERTIES TRUST, INC.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(RULE 14A-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE
SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT
NO. )
Filed by the Registrant þ
Filed by a Party other than the
Registrant o
Check the appropriate box:
o Preliminary
Proxy Statement
|
|
o |
Confidential, For Use of the Commission Only (as permitted by
Rule 14a-6(e)(2)) |
þ Definitive Proxy
Statement
o Definitive
Additional Materials
|
|
o |
Soliciting Material Pursuant to Rule 14a-12 |
MEDICAL PROPERTIES TRUST, INC.
(Name of Registrant as Specified in Its Charter)
Not Applicable
(Name of Person(s) Filing Proxy Statement, if Other Than the
Registrant)
Payment of Filing Fee (Check the appropriate box):
o Fee computed on
table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
(1) |
Title of each class of securities to which transaction applies: |
|
|
(2) |
Aggregate number of securities to which transaction applies: |
|
|
(3) |
Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on
which the filing fee is calculated and state how it was
determined): |
|
|
(4) |
Proposed maximum aggregate value of transaction: |
|
|
o |
Fee paid previously with preliminary materials: |
|
o |
Check box if any part of the fee is offset as provided by
Exchange Act Rule 0-11(a)(2) and identify the filing for
which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or
Schedule and the date of its filing. |
|
|
(1) |
Amount previously paid: |
|
|
(2) |
Form, Schedule or Registration Statement No.: |
Medical Properties Trust, Inc.
1000 Urban Center Drive, Suite 501
Birmingham, Alabama 35242
(205) 969-3755
www.medicalpropertiestrust.com
September 13, 2005
Dear Fellow Stockholder,
It is with great pleasure that I, on behalf of the Board of
Directors, invite you to attend on October 12, 2005 our
first annual stockholders meeting since our initial public
offering. We are honored to have you as one of our stockholders
and hope that you will be able to attend the meeting. In the
event that you are unable to attend, however, it is important
that your shares are represented; therefore, please be sure to
sign, date, and mail your proxy in the provided envelope at your
earliest convenience.
|
|
|
Best Regards, |
|
|
|
|
|
Edward K. Aldag, Jr. |
|
Chairman, President and CEO |
Medical Properties Trust, Inc.
1000 Urban Center Drive, Suite 501
Birmingham, Alabama 35242
(205) 969-3755
www.medicalpropertiestrust.com
NOTICE OF
2005 ANNUAL MEETING OF STOCKHOLDERS
October 12, 2005
To Our Stockholders:
The 2005 Annual Meeting of Stockholders of Medical Properties
Trust, Inc. (the Company) will be held at The Summit
Club, 1901 6th Avenue North, Birmingham, Alabama, on
October 12, 2005, beginning at 10:00 a.m. Central
Time, for the following purposes:
|
|
|
|
1. |
To elect eight directors; |
|
|
2. |
To approve amendments to the Companys Charter regarding
transfer or ownership restrictions on the Companys common
stock; |
|
|
3. |
To approve an amendment to the Amended and Restated Medical
Properties Trust, Inc. 2004 Equity Incentive Plan to increase by
3,900,000 the number of shares of common stock available (from
2,052 shares as of August 31, 2005) for future awards
thereunder; and |
|
|
4. |
To transact any other business that properly comes before the
meeting. |
Only stockholders of record at the close of business on
September 7, 2005, are entitled to receive notice of and to
vote at the meeting and any adjournment thereof.
EVEN IF YOU PLAN TO ATTEND IN PERSON, YOU ARE REQUESTED TO SIGN,
DATE, AND RETURN THE ENCLOSED PROXY IN THE ACCOMPANYING
POSTAGE-PAID ENVELOPE AT YOUR EARLIEST CONVENIENCE. This will
not prevent you from voting your shares in person if you choose
to attend the Annual Meeting.
|
|
|
By Order of the Board of Directors, |
|
|
|
|
Michael G. Stewart |
|
Executive Vice President, |
|
General Counsel and Secretary |
September 13, 2005
Medical Properties Trust, Inc.
1000 Urban Center Drive, Suite 501
Birmingham, Alabama 35242
205-969-3755
www.medicalpropertiestrust.com
PROXY STATEMENT
for
2005 ANNUAL MEETING OF STOCKHOLDERS
October 12, 2005
GENERAL INFORMATION
This Proxy Statement is being furnished to the stockholders of
Medical Properties Trust, Inc. (the Company) in
connection with the solicitation of proxies by the Board of
Directors of the Company to be voted at the 2005 Annual Meeting
of Stockholders to be held at The Summit Club, 1901
6th Avenue North, Birmingham, Alabama, on October 12,
2005, beginning at 10:00 a.m. Central Time, and at any
adjournment thereof.
At the meeting, the Companys stockholders will be asked to
vote on proposals to (1) elect eight directors;
(2) approve amendments to the Companys Charter
regarding transfer or ownership restrictions on the
Companys common stock as requested by the New York Stock
Exchange; and (3) approve an amendment to the Amended and
Restated Medical Properties Trust, Inc. 2004 Equity Incentive
Plan to increase by 3,900,000 the number of shares of common
stock available (from 2,052 shares as of August 31,
2005) for future awards thereunder. Stockholders will also
transact any other business that properly comes before the
meeting, although as of the date of this Proxy Statement the
Board of Directors knows of no such other business to be
presented. When you submit your proxy, by executing and
returning the enclosed proxy card, you will authorize the
persons named in the enclosed proxy to represent you and vote
your shares of the Companys common stock on these
proposals as specified by you. If no such specification is made,
shares represented by your proxy will be voted
|
|
|
|
|
FOR the election of the eight director nominees; |
|
|
|
FOR the approval of amendments to the Companys Charter
regarding transfer or ownership restrictions on the
Companys common stock; and |
|
|
|
FOR the approval to the amendment of the Amended and Restated
Medical Properties Trust, Inc. 2004 Equity Incentive Plan to
increase by 3,900,000 the number of shares of common stock
available (from 2,052 shares as of August 31, 2005)
for future awards thereunder. |
The proxy holders will also have discretionary authority to vote
your shares on any other business that properly comes before the
meeting.
This Proxy Statement and the accompanying materials are first
being sent or given to the Companys stockholders on or
about September 13, 2005.
1
INFORMATION ABOUT THE MEETING
What is the purpose of the meeting?
At the meeting, the Companys stockholders will vote on
proposals:
|
|
|
|
1. |
To elect eight directors; |
|
|
2. |
To approve amendments to the Companys Charter regarding
transfer or ownership restrictions on the Companys common
stock; and |
|
|
3. |
To approve an amendment to the Amended and Restated Medical
Properties Trust, Inc. 2004 Equity Incentive Plan to increase by
3,900,000 the number of shares of common stock available (from
2,052 shares as of August 31, 2005) for future awards
thereunder. |
In addition, the Companys management will report on the
performance of the Company at the meeting and respond to
appropriate questions from stockholders.
Who is entitled to vote?
The record date for the meeting is September 7, 2005. Only
stockholders of record at the close of business on
September 7, 2005 are entitled to receive notice of the
meeting and to vote at the meeting the shares of the
Companys common stock that they held of record on that
date. Each outstanding share of common stock entitles its holder
to one vote on each matter voted on at the meeting. At the close
of business on September 7, 2005, there were outstanding
and entitled to vote 39,969,065 shares of common stock.
Am I entitled to vote if my shares are held in street
name?
If you are the beneficial owner of shares held in street
name by a brokerage firm, bank, or other nominee, such
entity is required to vote the shares in accordance with your
instructions. If you do not give instructions to your nominee,
it will nevertheless be entitled to vote your shares on
discretionary items but will not be permitted to do
so on non-discretionary items. The Company has been
informed that Proposal 1 (election of directors) and
Proposal 2 (approval of the amendments to the Charter) are
discretionary items on which your nominee will be entitled to
vote your shares even in the absence of instructions from you,
but that Proposal 3 (approval of the amendment to the
Equity Incentive Plan) is a non-discretionary item on which your
nominee will not be entitled to vote your shares unless you
provide it with instructions.
How many shares must be present to conduct business at the
meeting?
A quorum must be present at the meeting in order for any
business to be conducted. The presence at the meeting, in person
or by proxy, of the holders of a majority of the shares of the
Companys common stock outstanding on the record date will
constitute a quorum. Abstentions and broker non-votes will be
included in the number of shares considered present at the
meeting for the purpose of determining whether there is a quorum.
What happens if a quorum is not present at the meeting?
If a quorum is not present at the scheduled time of the meeting,
the holders of a majority of the shares present in person or
represented by proxy at the meeting may adjourn the meeting to
another place, date, or time until a quorum is present. The
place, date, and time of the adjourned meeting will be announced
when the adjournment is taken, and no other notice will be given
unless the adjournment is to a date more than 120 days
after the original record date or if, after the adjournment, a
new record date is fixed for the adjourned meeting.
2
How do I vote my shares?
If your shares are held in street name, you may
be eligible to provide voting instructions to your nominee by
telephone or on the Internet. If you are a beneficial owner
of shares held in street name (i.e., your
shares are held in the name of a brokerage firm, bank, or other
nominee), you may be eligible to provide voting instructions to
your nominee by telephone or on the Internet. A large number of
brokerage firms, banks, and other nominees participate in a
program provided through ADP Investor Communications Services
that offers telephone and Internet voting options. If your
shares are held in street name by a brokerage firm,
bank, or other nominee that participates in the ADP program, you
may provide voting instructions to your nominee by telephone or
on the Internet by following the instructions set forth on the
voting instruction form provided to you.
You may vote by mail. If you are a registered
stockholder, you may vote by properly completing, signing,
dating, and returning the accompanying proxy card. The enclosed
postage-paid envelope requires no additional postage if it is
mailed in the United States or Canada. If you are a beneficial
owner of shares held in street name, you may provide
voting instructions to the brokerage firm, bank, or other
nominee that holds your shares by properly completing, signing,
dating, and returning the voting instruction form provided to
you by your nominee.
You may vote in person at the meeting. If you are a
registered stockholder and attend the meeting, you may deliver
your completed proxy card in person. In addition, the Company
will pass out written ballots to registered stockholders who
wish to vote in person at the meeting. If you are a beneficial
owner of shares held in street name and wish to vote
at the meeting, you will need to obtain a proxy form from the
brokerage firm, bank, or other nominee that holds your shares
that authorizes you to vote those shares.
Can I change my vote after I submit my proxy?
Yes, you may revoke your proxy and change your vote at any time
before the polls are closed at the meeting in any of the
following ways: (1) by properly completing, signing,
dating, and returning another proxy card with a later date;
(2) if you are a registered stockholder, by voting in
person at the meeting; (3) if you are a registered
stockholder, by giving written notice of such revocation to the
Secretary of the Company prior to or at the meeting; or
(4) if you are a beneficial owner of shares held in
street name, by following the instructions given by
the brokerage firm, bank, or other nominee that holds your
shares. Your attendance at the meeting itself will not revoke
your proxy.
How does the Board of Directors recommend that I vote on the
proposals?
Your Board of Directors recommends that you vote FOR the
following proposals:
|
|
|
|
1. |
The election of eight nominees to the Board of Directors; |
|
|
2. |
The approval of amendments to the Companys Charter
regarding transfer or ownership restrictions on the
Companys common stock; and |
|
|
3. |
The approval of an amendment to the Amended and Restated Medical
Properties Trust, Inc. 2004 Equity Incentive Plan to increase by
3,900,000 the number of shares of common stock available for
awards thereunder. |
What happens if I do not specify on my proxy how my shares
are to be voted?
If you submit a proxy to the Company but do not indicate any
voting instructions, your shares will be voted FOR each of the
proposals.
Will any other business be conducted at the meeting?
As of the date hereof, the Board of Directors knows of no
business that will be presented at the meeting other than the
proposals described in this Proxy Statement. However, if any
other proposal properly comes
3
before the stockholders for a vote at the meeting, the proxy
holders will vote the shares represented by your proxy in
accordance with their best judgment.
How many votes are required for action to be taken on each
proposal?
Election of Directors. The eight director nominees
will be elected to serve on the Board of Directors if they
receive a plurality of the votes cast at the meeting. This means
that the eight director nominees will be elected if they receive
more votes than any other person at the meeting. If you vote to
Withhold Authority with respect to the election of
one or more director nominees, your shares will not be voted
with respect to the person or persons indicated, although they
will be counted for the purpose of determining whether there is
a quorum at the meeting.
Approval of Amendment of the Charter. The proposed
amendments to the Companys Charter regarding transfer or
ownership restrictions on the Companys common stock will
be approved if at least two-thirds of all the votes entitled to
be cast on the matter are voted in favor of the proposal.
Approval of Amendment to Equity Incentive Plan.
The proposed amendment to the Amended and Restated
Medical Properties Trust, Inc. 2004 Equity Incentive Plan will
be approved if a majority of all of the votes cast at the
meeting are voted in favor of the proposal.
How will abstentions be treated?
You do not have the option of abstaining from voting on
Proposal 1 (election of directors), but you may abstain
from voting on Proposal 2 (approval of the amendments to
the Charter) and Proposal 3 (approval of the amendment to
the Equity Incentive Plan). In the case of an abstention on
Proposal 2, your abstention will have the same effect as a
negative vote. With respect to Proposal 3, an abstention
will have no effect on the outcome of the vote.
How will broker non-votes be treated?
Broker non-votes will not have any effect on
Proposal 1 (election of directors) and Proposal 3
(approval of the amendment to the Equity Incentive Plan) but
will have a negative effect on the outcome of Proposal 2
(approval of amendments to the Charter).
4
PROPOSAL 1 ELECTION OF DIRECTORS
Director
Nominees
The Board of Directors proposes that the eight nominees listed
below, all of whom are currently serving on the Companys
Board, be elected to serve as directors of the Company until the
2006 annual meeting of stockholders and until his or her
successor is duly elected and qualified. The Board of Directors
does not know of any reason why any nominee would not be able to
serve as a director. However, if any nominee were to become
unable to serve as a director, the Board of Directors may
designate a substitute nominee, in which case the persons named
as proxies will vote for such substitute nominee. Alternatively,
the Board of Directors may reduce the number of directors to be
elected at the annual meeting.
Edward K. Aldag, Jr. Mr. Aldag,
age 41, is one of our founders and has served as our Chief
Executive Officer and President since August 2003, and as
Chairman of the Board since March 2004. Mr. Aldag served as
our Vice Chairman of the Board of Directors from August 2003
until March 2004 and as our Secretary from August 2003 until
March 2005. Prior to that, Mr. Aldag served as an executive
officer and director with our predecessor from its inception in
August 2002 until August 2003. From 1986 to 2001, Mr. Aldag
managed two private real estate companies, Guilford Capital
Corporation and Guilford Medical Properties, Inc. Mr. Aldag
served as President and a member of the Board of Directors of
Guilford Medical Properties, Inc. Mr. Aldag was the
President of Guilford Capital Corporation from 1998 to 2001 and
from 1990 to 1998 served as Executive Vice President, Chief
Operating Officer and was a member of the Board of Directors
from 1990 to 2001. Mr. Aldag received his B.S. in
Commerce & Business from the University of Alabama with
a major in corporate finance.
Virginia A. Clarke. Ms. Clarke, age 46,
has served as a member of our Board of Directors since February
2005. Ms. Clarke has been a search consultant in the global
executive search firm of Spencer Stuart & Associates
since 1997. Ms. Clarke was with DHR International, an
executive search firm, during 1996. Prior to that,
Ms. Clarke spent 10 years in the real estate
investment management business with La Salle Partners and
Prudential Real Estate Investors, where her activities included
asset management, portfolio management, capital raising and
client service, and two years with First National Bank of
Chicago. Ms. Clarke is a member of the Pension Real Estate
Association. Ms. Clarke graduated from the University of
California at Davis and received a masters degree in
management from the J. L. Kellogg Graduate School of Management
at Northwestern University.
G. Steven Dawson. Mr. Dawson, age 47,
has served as a member of our Board of Directors since April
2004. He is currently a private investor and serves on the
boards of five other real estate investment trusts in addition
to his service for us, as follows: American Campus Communities
(NYSE: ACC), AmREIT, Inc. (AMEX: AMY), Desert Capital REIT (a
non-listed public mortgage company), Sunset Financial Resource,
Inc. (NYSE: SFO), and Trustreet Properties, Inc. (NYSE: TSY).
Mr. Dawson is chairman of the audit committees for each of
these companies except Sunset Financial Resource, Inc. and
Trustreet Properties, Inc. From July 1990 to September 2003, he
was Chief Financial Officer and Senior Vice President-Finance of
Camden Property Trust (NYSE: CPT) and its predecessors, a REIT
engaged in the development, ownership, management, financing and
sale of multi-family properties throughout the southern United
States. Mr. Dawson is involved in various charitable,
non-profit and educational organizations, including serving on
the board of His Grace Foundation, a charity providing services
to the families of children in the Bone Marrow Transplant Unit
of Texas Childrens Hospital, and as a member of the Real
Estate Roundtable at the Mays Graduate School of Business at
Texas A&M University. Mr. Dawson received a degree in
business from Texas A&M University.
Bryan L. Goolsby. Mr. Goolsby, age 54, has
served as a member of our Board of Directors since February
2005. Mr. Goolsby is the Managing Partner of the law firm
Locke Liddell & Sapp LLP. Mr. Goolsby is an
associate board member of the Board of Governors of the National
Association of Real Estate Investment Trusts. He is also a
member of the National Multi-Family Housing Association and the
Pension Real Estate Association, and an associate board member
of the Edwin L. Cox School of Business at Southern Methodist
University. He serves as a director of Desert Capital REIT, Inc.
and AmREIT, Inc. Mr. Goolsby received a J.D. degree from
the University of Texas, and is a Certified Public Accountant.
5
R. Steven Hamner. Mr. Hamner, age 48,
is one of our founders and has served as our Executive Vice
President and Chief Financial Officer since September 2003 and
as a director since February 2005. In August and September 2003,
Mr. Hamner served as our Executive Vice President and Chief
Accounting Officer. From October 2001 through March 2004, he was
the Managing Director of Transaction Analysis LLC, a company
that provided interim and project-oriented accounting and
consulting services to commercial real estate owners and their
advisors. From June 1998 to September 2001, he was Vice
President and Chief Financial Officer of United Investors Realty
Trust, a publicly-traded REIT. For the 10 years prior to
becoming an officer of United Investors Realty Trust, he was
employed by the accounting and consulting firm of
Ernst & Young LLP and its predecessors. Mr. Hamner
received a B.S. in Accounting from Louisiana State University.
Mr. Hamner is a certified public accountant.
Robert E. Holmes, Ph.D. Mr. Holmes,
age 63, has served as a member of our Board of Directors
since April 2004. Mr. Holmes, our lead independent
director, is the Dean and Professor of Management of the School
of Business at the University of Alabama at Birmingham,
positions he has held since 1999. From 1995 to 1999, he was Dean
of the Olin Graduate School of Business at Babson College in
Wellesley, Massachusetts. Prior to that, he was Dean of the
James Madison University College of Business in Harrisonburg,
Virginia for 12 years. He is the author of more than 20
scholarly publications, is past president of the Southern
Business Administration Association, and is actively involved in
the International Association for Management Education.
Mr. Holmes received a bachelors degree from the
University of Texas at Austin, an MBA from University of North
Texas, and received his Ph.D. from the University of Arkansas
with an emphasis on management strategy.
William G. McKenzie. Mr. McKenzie, age 47,
is one of our founders and has served as the Vice Chairman of
our Board of Directors since September 2003. Mr. McKenzie
has served as a director since our formation and served as the
Executive Chairman of our Board of Directors in August and
September 2003. From May 2003 to August 2003, he was an
executive officer and director of our predecessor. From 1998 to
the present, Mr. McKenzie has served as President, Chief
Executive Officer and a board member of Gilliard Health
Services, Inc., a privately-held owner and operator of acute
care hospitals. From 1996 to 1998, he was Executive Vice
President and Chief Operating Officer of the Mississippi
Hospital Association/ Diversified Services, Inc. and the Health
Insurance Exchange, a mutual company and HMO. From 1994 to 1996,
Mr. McKenzie was Senior Vice President of Managed Care and
Executive Vice President of Physician Solutions, Inc., a
subsidiary of Vaughan HealthCare, a private healthcare company
in Alabama. From 1981 to 1994, Mr. McKenzie was Hospital
Administrator and Chief Financial Officer and held other
management positions with several private acute care
organizations. Mr. McKenzie received a Masters of Science
in Health Administration from the University of Colorado and a
B.S. in Business Administration from Troy State University. He
has served in numerous capacities with the Alabama Hospital
Association.
L. Glenn Orr, Jr. Mr. Orr,
age 65, has served as a member of our Board of Directors
since February 2005. Mr. Orr has been President and Chief
Executive Officer of The Orr Group, which provides investment
banking and consulting services for middle-market companies,
since 1995. Prior to that, he was Chairman of the Board of
Directors, President and Chief Executive Officer of Southern
National Corporation from 1990 until its merger with Branch
Banking & Trust in 1995. Mr. Orr is member of the
Board of Directors, chairman of the governance/compensation
committee and a member of the executive committee of Highwoods
Properties, Inc. (NYSE: HIW). He is also a member of the Boards
of Directors of General Parts, Inc., Village Tavern, Inc. and
Broyhill Management Fund, Inc. Mr. Orr previously served as
President and Chief Executive Officer of Forsyth Bank and Trust
Co., President of Community Bank in Greenville, South Carolina
and President of the North Carolina Bankers Association. He is a
trustee of Wake Forest University.
Board of Directors
Recommendation
THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR
EACH OF THE EIGHT NOMINEES FOR DIRECTOR LISTED ABOVE.
6
CERTAIN INFORMATION REGARDING
OUR BOARD OF DIRECTORS
The Board of Directors of the Company consists of eight
directors. The Companys current directors are Edward K.
Aldag, Jr., Virginia A. Clarke, G. Steven Dawson,
Bryan L. Goolsby, R. Steven Hamner, Robert E.
Holmes, Ph.D., and L. Glenn Orr, Jr. The
directors are elected at each annual meeting of stockholders and
serve until the next annual meeting of stockholders and until
their respective successors are elected and qualified, subject
to their prior death, resignation, retirement, disqualification,
or removal from office.
It is the policy of the Board of Directors that a majority of
the directors be independent as defined in the listing standards
of the New York Stock Exchange (the NYSE). The Board
of Directors has determined that five directors
Virginia A. Clarke, G. Steven Dawson, Bryan L.
Goolsby, Robert E. Holmes, Ph.D., and L. Glenn
Orr, Jr. are independent under the NYSEs
listing standards.
The Board of Directors holds regular meetings on a quarterly
basis and on other occasions as necessary or appropriate. The
Board of Directors met nine times in 2004. The Board of
Directors has four standing committees: the Audit Committee, the
Compensation Committee, the Ethics, Nominating and Corporate
Governance Committee, and the Investment Committee. Each
director attended at least 75% of the total number of meetings
of the Board of Directors and its committees on which he served
in 2004.
In connection with each of its regular meetings, the Board of
Directors meets in executive session in which management
directors are not present. Mr. Holmes has been designated
as the Companys lead independent director and in that
capacity presides at these executive sessions, coordinates the
preparation for meetings of the Board of Directors with our
Chief Executive Officer, and serves as the liaison between the
Board of Directors and our Chief Executive Officer. The
directors of the Company are encouraged to attend the
Companys annual meeting of stockholders absent cause. In
2004 all directors attended the annual meeting of stockholders.
Committees
of the Board of Directors
The Board of Directors delegates certain of its functions to its
standing Audit Committee, Compensation Committee, Ethics,
Nominating and Corporate Governance Committee, and Investment
Committee.
The Audit Committee is comprised of three
independent directors, Messrs. Dawson and Orr and
Ms. Clarke. Mr. Dawson serves as the chairperson. The
Board of Directors has determined that each member of the Audit
Committee is financially literate and satisfies the additional
independence requirements for audit committee members, that
Mr. Dawson qualifies as an audit committee financial
expert under current SEC regulations, and that his service
on three other public companies audit committees does not
impair his ability to serve on our Audit Committee.
The Audit Committee oversees (i) our accounting and
financial reporting processes; (ii) the integrity and
audits of our financial statements; (iii) our compliance
with legal and regulatory requirements; (iv) the
qualifications and independence of our independent auditors; and
(v) the performance of our internal and independent
auditors. The specific functions and responsibilities of the
Audit Committee are set forth in the Audit Committee Charter, a
copy of which is attached as Appendix A and which also is
posted on the Companys website at
www.medicalpropertiestrust.com. The information on the
Companys website is not part of this Proxy Statement. The
report of the Audit Committee begins on page 18 of this
Proxy Statement.
The Compensation Committee is comprised of three
independent directors, Messrs. Dawson, Goolsby, and Orr.
Mr. Orr serves as the chairperson of the Compensation
Committee.
The principal functions of the Compensation Committee are to
evaluate the performance of our executive officers; review and
approve the compensation for our executive officers; review and
make recommendations to the Board of Directors with respect to
our incentive compensation plans and equity-based plans; and
administer our equity incentive plan. The Compensation Committee
also reviews and approves corporate goals and objectives
relevant to the Chief Executive Officers compensation,
evaluates the Chief Executive Officers
7
performance in light of those goals and objectives, and
establishes the Chief Executive Officers compensation
levels. The specific functions and responsibilities of the
Compensation Committee are set forth in more detail in the
Compensation Committees Charter, a copy of which is posted
on the Companys website at www.medicalpropertiestrust.com.
The report of the Compensation Committee begins on page 23
of this Proxy Statement.
The Ethics, Nominating, and Corporate Governance Committee
is comprised of three independent directors,
Messrs. Dawson, Goolsby and Holmes. Mr. Holmes serves
as the chairperson of the Committee. The Ethics, Nominating and
Corporate Governance Committee is responsible for, among other
things, recommending the nomination of qualified individuals to
become directors; recommending the composition of committees of
our Board of Directors; periodically reviewing the Board of
Directors performance and effectiveness as a body; recommending
proposed changes to the Board of Directors; and periodically
reviewing our corporate governance guidelines and policies. The
specific functions and duties of the Committee are set forth in
its Charter, a copy of which is posted on the Companys
website at www.medicalpropertiestrust.com.
The Ethics, Nominating and Corporate Governance Committee will
consider all potential candidates for nomination for election as
directors who are recommended by the Companys
stockholders, directors, officers, and employees. All director
recommendations must be made during the time periods, and must
provide the information, required by Article II,
Section 2.03 of the Companys Amended and Restated
Bylaws. All director recommendations should be sent to the
Ethics, Nominating and Corporate Governance Committee,
c/o Secretary, Medical Properties Trust, Inc., 1000 Urban
Center Drive, Suite 501, Birmingham, Alabama 35242. The
Committee will screen all potential director candidates in the
same manner, regardless of the source of their recommendation.
The Committees review will typically be based on the
written materials provided with respect to a potential director
candidate. The Committee will evaluate and determine whether a
potential candidate meets the Companys minimum
qualifications and requirements, whether the candidate has
specific qualities and skills for directors, and whether
requesting additional information or an interview is appropriate.
The Board of Directors has adopted the following minimum
qualifications and specific qualities and skills for the
Companys directors, which will serve as the basis upon
which potential director candidates are evaluated by the Ethics,
Nominating and Corporate Governance Committee:
(i) directors should possess the highest personal and
professional ethics, integrity, and values; (ii) directors
should have, or demonstrate an ability and willingness to
acquire, in short order, a clear understanding of the
fundamental aspects of the Companys business;
(iii) directors should be committed to representing the
long-term interests of the Companys stockholders;
(iv) directors should be willing to devote sufficient time
to carry out their duties and responsibilities effectively and
should be committed to serving on the Board of Directors for an
extended period of time; and (v) directors should not serve
on more than five boards of public companies in addition to the
Companys Board of Directors.
The Ethics, Nominating and Corporate Governance Committee has
recommended the nomination of all eight of the incumbent
directors for re-election. The entire Board of the Company has
approved such recommendation.
The Investment Committee membership is comprised
of all of our current directors. Mr. Aldag serves as the
chairperson of the committee. The Investment Committee has the
authority to, among other things, consider and take action with
respect to all acquisitions, developments, and leasing of
healthcare facilities in which our aggregate investment will
exceed $10 million.
Director
Compensation
As compensation for serving on our Board, each independent
director receives an annual fee of $20,000, plus $1,000 for
each Board of Directors meeting and each committee meeting
attended as a member. Committee chairmen receive an additional
$5,000 per year, except for the Audit Committee chairman
who receives an additional $10,000 per year. We also
reimburse our directors for reasonable expenses incurred in
attending these meetings. At each annual stockholders meeting
following the election of an independent director, that director
will receive 2,000 shares of our common stock, restricted
as to transfer for three years, or
8
a comparable number of deferred stock units. Our Compensation
Committee may change the compensation of our independent
directors in its discretion.
Directors who are also officers or employees of the Company
receive no additional compensation for their service as
directors.
Upon joining our Board of Directors, each of our current
independent directors received a non-qualified option to
purchase 20,000 shares of our common stock with an
exercise price of $10.00 per share. One-third of these
options vested upon grant. One-half of the remaining options
have vested or will vest on each of the first and second
anniversaries of the date of grant. In addition to this option
to purchase stock, Messrs. Dawson and Holmes were awarded
2,500 deferred stock units, which represent the right to receive
2,500 shares of common stock at no cost in October 2007.
Governance,
Ethics, and Stockholder Communications
Corporate Governance Guidelines. In furtherance of
its goal of providing effective governance of the Companys
business and affairs for the long-term benefit of its
stockholders, the Board of Directors has approved and adopted
Corporate Governance Guidelines. The Corporate Governance
Guidelines are posted on the Companys website at
www.medicalpropertiestrust.com.
Code of Ethics and Business Conduct. The Company
has adopted a Code of Ethics and Business Conduct which applies
to all directors, officers, employees and agents of the Company
and its subsidiaries. The Code of Ethics and Business Conduct is
posted on the Companys website at
www.medicalpropertiestrust.com.
Stockholder Communications. Stockholders may
communicate with the Board of Directors or any individual
director regarding any matter relating to the Company that is
within the responsibilities of the Board of Directors.
Stockholders should send their communications to the Board of
Directors, or an individual director, c/o Secretary,
Medical Properties Trust, Inc., 1000 Urban Center Drive,
Suite 501, Birmingham, Alabama. The Secretary will review
the correspondence and forward any stockholder communication to
the Board of Directors, or the individual director, if the
Secretary determines that the communication deals with the
functions of the Board of Directors or requires the attention of
the Board of Directors or the individual director. The Secretary
will maintain a log of all communications received from
stockholders.
PROPOSAL 2 APPROVAL OF AMENDMENTS TO THE
CHARTER
The Board of Directors has adopted a resolution proposing
amendments to the Companys Second Articles of Amendment
and Restatement (the Charter), as requested by the
New York Stock Exchange, regarding transfer or ownership
restrictions on the Companys common stock.
Summary
of Proposed Amendment
In April 2005, the Company filed a listing application with the
NYSE, pursuant to which the NYSE reviewed the Companys
Charter. In connection with such review, the NYSE has indicated
that the Company should revise certain provisions of its Charter
to modify the transfer or ownership restrictions on the
Companys common stock that may impair the settlement of
transactions on the NYSE. Accordingly, the Board of Directors
has adopted a resolution declaring that it is advisable that the
Charter be amended as described below.
Text
of Amendments
If the proposed amendments to the Charter are approved by the
stockholders, Section 6.2.1(a)(iii) will be amended by
deleting the parenthetical phrase (whether or not such
Transfer is the result of a transaction entered into through the
facilities of the NYSE or any other national securities exchange
or automated inter-
9
dealer quotation system) following the phrase any
Transfer of shares of Capital Stock in the second sentence
thereof so that said Section 6.2.1(a)(iii), as amended,
will read as follows:
|
|
|
(iii) No Person shall Transfer any shares of Capital Stock
if, as a result of the Transfer, the outstanding shares of all
classes and series of Capital Stock would be Beneficially Owned
by less than 100 Persons (determined without reference to the
rules of attribution under Section 544 of the Code).
Subject to Section 6.5 of this Article VI and
notwithstanding any other provisions contained herein, any
Transfer of shares of Capital Stock that, if effective, would
result in outstanding shares of all classes and series of
Capital Stock being Beneficially Owned by less than 100 Persons
(determined under the principles of Section 856(a)(5) of
the Code) shall be void ab initio, and the intended transferee
shall acquire no rights in such shares of Capital Stock. |
If the proposed amendments to the Charter are approved by the
stockholders, Section 6.4.1(b) will be amended by adding
the phrase Subject to Section 6.5 of this
Article VI, at the beginning of the first sentence
thereof so that said Section 6.4.1(b), as amended, will
read as follows:
|
|
|
(b) Subject to Section 6.5 of this Article VI, if
and to the extent that any class or series of shares of Capital
Stock do not constitute Publicly Offered Securities, then no
Person shall Transfer any shares of such Capital Stock if, as a
result of the Transfer, the Benefit Plan Investors, on any date,
hold, individually or in the aggregate, 25 percent or more
of the value of such class or series of shares of Capital Stock
in violation of 6.4.1(a). |
If the proposed amendments to the Charter are approved by the
stockholders, Section 6.4.2(a) will be amended by adding
the phrase Subject to Section 6.5 of this
Article VI, at the beginning of the first sentence
thereof and by deleting the parenthetical phrase (whether
or not such Transfer is the result of a transaction entered into
through the facilities of the NYSE or any other national
securities exchange or automated inter-dealer quotation
system) following the words any Transfers of shares
of Capital Stock in the first sentence thereof so that
said Section 6.4.2(a), as amended, will read as follows:
|
|
|
(a) Subject to Section 6.5 of this Article VI, if
any Transfers of shares of Capital Stock occurs which, if
effective, would result in any of the Benefit Plan Investors, on
any date, holding, individually or in the aggregate,
25 percent or more of the value of such class or series of
shares of Capital Stock in violation of 6.4.1 or would otherwise
result in the underlying assets and property of the Corporation
becoming assets of any ERISA Investor: |
|
|
|
(i) then that number of shares of Capital Stock the holding
of which otherwise would cause any Person to violate
Section 6.4.1 (rounded upward to the nearest whole share)
shall be automatically transferred to a Charitable Trust for the
benefit of a Charitable Beneficiary, as described in
Section 6.3, effective as of the close of business on the
Business Day prior to the date of such Transfer, and such Person
shall acquire no rights in such shares of Capital Stock; or |
|
|
(ii) if the transfer to the Charitable Trust described in
clause (i) of this sentence would not be effective for any
reason to prevent the violation of Section 6.4.1, then the
Transfer of that number of shares of Capital Stock that
otherwise would cause any Person to violate Section 6.4.1
shall be void ab initio, and the intended transferee shall
acquire no rights in such shares of Capital Stock. |
Effects
of Amendment
If the proposed amendments, which are to be voted on together
and not separately, are approved by the stockholders, the
provisions in the Charter relating to transfer and ownership
restrictions will not impair the settlement of transactions
entered into through the facilities of the New York Stock
Exchange.
Effective
Date of Amendment
If the proposed amendments are approved by the stockholders, the
Company intends shortly thereafter to file the Third Articles of
Amendment and Restatement with the office of the Secretary of
State of the State of
10
Maryland. The Third Articles of Amendment and Restatement will
become effective upon its filing. The only changes to the
Charter will be those shown above.
Board
of Directors Recommendation
BASED ON THE REQUEST OF THE NEW YORK STOCK EXCHANGE AND OUR
REVIEW OF THAT REQUEST, THE BOARD OF DIRECTORS RECOMMENDS THAT
YOU VOTE FOR THE APPROVAL OF THE FOREGOING AMENDMENTS TO THE
COMPANYS CHARTER REGARDING TRANSFER OR OWNERSHIP
RESTRICTIONS ON THE COMPANYS COMMON STOCK.
PROPOSAL 3 APPROVAL OF AMENDMENT OF EQUITY
INCENTIVE PLAN
In an effort to ensure that the goals and incentives of the
executive officers, employees, consultants, and directors of the
Company are fully aligned with those of the stockholders, the
Companys 2004 Equity Incentive Plan was adopted by the
Board of Directors and approved by the stockholders in March
2004 and was subsequently amended and restated in October 2004.
Under the Equity Incentive Plan, the Company is authorized to
grant equity-based awards in the form of stock options,
restricted common stock, restricted stock units, deferred stock
units, stock appreciation rights, and performance share units to
the employees (including executive officers), directors, and
consultants of the Company and its affiliates and subsidiaries.
Summary
of Proposed Amendment
After reviewing the current status of the Equity Incentive Plan,
the Board of Directors has concluded that it is in the best
interests of the Company and its stockholders for the Equity
Incentive Plan to be amended as described below. The Board of
Directors has adopted an amendment to the Equity Incentive Plan
to effect this change, subject to approval by the Companys
stockholders. If approved by the stockholders, the amendment
will become effective October 12, 2005.
Making
Shares Available Under the Plan
The Board of Directors believes it is in the interests of the
stockholders of the Company that the executive officers,
directors, employees, and consultants of the Company be given
long term incentives in the form of awards under the Equity
Incentive Plan to ensure that their goals and incentives are
aligned with those of the stockholders. As of August 31,
2005, management, directors, and employees own approximately
3.46% of the outstanding shares of the Company. The Board
believes it is important to continue to increase the amount of
stock in the Company that management, directors, and employees
have at risk. As of August 31, 2005, the Equity Incentive
Plan had 2,052 shares available for future awards out of
the total of 791,180 shares originally reserved for awards
under the Plan.
Summary
of Equity Incentive Plan
The statements contained in the following summary are qualified
by reference to the Amended and Restated Medical Properties
Trust, Inc. 2004 Equity Incentive Plan. A copy of the Plan,
including the proposed amendment, is attached as Appendix B
to this Proxy Statement.
Under the Equity Incentive Plan, the Company may grant
non-qualified stock options, restricted stock, restricted stock
units, deferred stock units, stock appreciation rights (or
SARs), and performance share units to employees,
consultants, and directors of the Company and its affiliates.
Additionally, incentive stock options may be granted to
employees only. The Board of Directors may terminate or suspend
the Equity Incentive Plan at any time. The maximum number of
shares of common stock which may be awarded to any one person
during any one year is 300,000 shares.
Administration. The Compensation Committee of the
Board of Directors is authorized to administer the Equity
Incentive Plan. Subject to Compensation Committee review and
approval, the CEO makes recommen-
11
dations to the committee as to which consultants, employees, and
executive officers, other than himself, will be eligible to
participate. The Compensation Committee has the power, subject
to the provisions of the Equity Incentive Plan, to determine the
nature and extent of the awards to be made to each participant;
to determine the time when awards will be made to participants;
to establish the performance goals and determine the period of
time within which performance is measured with respect to
performance units; to establish the various targets and bonus
amounts which may be earned by certain employees; to specify the
relationship between the performance goals and the targets and
amounts that may be earned by certain employees; to determine
the period of time during which shares of restricted stock are
subject to restrictions; to determine the conditions for the
payment of awards; and to prescribe the forms of agreements and
documents evidencing the awards. The Compensation Committee, in
its absolute discretion subject to any applicable employment
agreement, will determine the effect of any matter related to
the termination of an employee.
Types
of Equity-Based Awards
Stock Options. The Compensation Committee may
grant stock options to eligible persons under the Equity
Incentive Plan. Each option granted pursuant to the Plan is
designated at the time of grant as either a qualified incentive
option or as a non-qualified option. Nonqualified stock options
may be granted to all eligible persons, but incentive stock
options may be granted only to employees of the Company and its
related entities.
Restricted Common Stock. Participants rights
with respect to grants of restricted common stock awarded under
the Plan are subject to transferability and forfeiture
restrictions during a restricted period. While the restrictions
are in place, the participant generally has the rights and
privileges of a stockholder, including the right to vote the
restricted common stock and to receive dividends.
Restricted Stock Units and Deferred Stock Units.
Each restricted stock unit and deferred stock unit
awarded by the Compensation Committee entitles the participant
to receive one share of common stock for each unit at the end of
the vesting or deferral periods. A holder of restricted stock
units or deferred stock units has no voting rights, right to
receive cash distributions, or other rights as a stockholder
until shares of common stock are issued to the holder in
settlement of the stock units. Participants holding restricted
stock units or deferred stock units are entitled to receive
dividend equivalents with respect to any payment of cash
dividends on an equivalent number of shares of common stock. The
dividend equivalents are credited in the form of additional
stock units.
Stock Appreciation Rights. SARs are awards
that give the recipient the right to receive an amount equal to
(1) the number of shares exercised under the right,
multiplied by (2) the amount by which our stock price
exceeds the exercise price. Payment may be in cash, in shares of
our common stock with equivalent value, or in some combination,
as determined by the Compensation Committee. SARs expire under
the same rules that apply to stock options.
Performance Units. Holders of performance
units will be entitled to receive payment in cash or shares of
our common stock (or in some combination of cash and shares) if
the performance goals established by the Compensation Committee
are achieved or the awards otherwise vest.
Change
of Control Provisions
Under the Equity Incentive Plan, if the Company experiences a
change of control as defined in the Equity Incentive Plan, a
participants then unvested options will automatically vest
and be fully exercisable, unless otherwise provided in the
participants award agreement or employment agreement, and
restricted stock, restricted stock units, and deferred stock
units will vest and no longer be subject to forfeiture if so
provided in the participants award agreement.
12
Federal
Income Tax Consequences
The following is a summary of the material United States federal
income tax consequences of the Equity Incentive Plan to the
Company and the participants. The summary is based on current
federal income tax law, which is subject to change, and does not
address state, local, or foreign tax consequences or
considerations.
Stock Options. The grant of stock options
under the Equity Incentive Plan will not result in taxable
income at the time of the grant for either the Company or the
optionee. Upon exercising an incentive stock option, the
optionee will have no taxable income (except that the
alternative minimum tax may apply) and the Company will receive
no deduction. Upon exercising a nonqualified stock option, the
optionee will recognize ordinary income in the amount by which
the fair market value of the common stock at the time of
exercise exceeds the option exercise price, and the Company will
be entitled to a deduction for the same amount. The
optionees income is subject to withholding tax as wages.
The tax treatment of the optionee upon a disposition of shares
of common stock acquired through the exercise of a stock option
is dependent upon the length of time that the shares have been
held and on whether such shares were acquired by exercising an
incentive stock option or a nonqualified stock option. If an
employee exercises an incentive stock option and holds the
shares for two years from the date of grant and one year after
exercise, then any gain or loss realized based on the exercise
price of the option will be treated as long-term capital gain or
loss. Shares obtained upon exercise of an incentive stock option
that are sold without satisfying these holding periods will be
treated as shares received from the exercise of a nonqualified
stock option. Generally, upon the sale of shares obtained by
exercising a nonqualified stock option, the optionee will treat
the gain realized on the sale as a capital gain. Generally,
there will be no tax consequence to the Company in connection
with the disposition of shares of common stock acquired under an
option, except that the Company may be entitled to a deduction
in the case of a disposition of shares acquired upon exercise of
an incentive stock option before the applicable holding periods
have been satisfied.
Restricted Stock. An award of restricted
stock will not result in taxable income to the participant at
the time of grant. Upon the lapse of the restrictions, the
participant will recognize ordinary income in the amount of the
fair market value of the shares of common stock at the time that
the restriction lapses. Alternatively, within 30 days after
receipt of the restricted stock, a participant may make an
election under Section 83(b) of the Code, which would allow
the participant to include in income in the year that the
restricted common stock is awarded an amount equal to the fair
market value of the restricted stock on the date of such award
determined as if the restricted common stock were not subject to
restrictions.
The Company will be entitled to a deduction for the year in
which the participant recognizes ordinary income with respect to
the restricted stock in an amount equal to such income.
Other Awards. The current federal income tax
consequences of other awards authorized under the 2004 Equity
Incentive Plan generally follow certain basic patterns: SARs,
Restricted Stock Units and Deferred Stock Units are taxed and
deductible in substantially the same manner as nonqualified
stock options, except to the extent Section 409A of the
Internal Revenue Code applies, in which case recipients would be
taxed at the time these items cease to be subject to substantial
risk of forfeiture. Nontransferable restricted stock subject to
a substantial risk of forfeiture results in income recognition
equal to the excess of the fair market value over the price paid
(if any) only at the time the restrictions lapse (unless the
recipient elects to accelerate recognition as of the date of
grant). Stock based performance awards, dividend equivalents and
other types of awards are generally subject to tax at the time
of payment. In each of the foregoing cases, the Company will
generally have a corresponding deduction at the time the
participant recognizes income.
Common
Stock Price
The last sale price of the Companys common stock on
August 31, 2005, as reported by the New York Stock
Exchange, was $11.00 per share.
Award Grants
Past Award Grants. The table below sets forth
information as of August 31, 2005, regarding (a) the
number of shares of common stock issuable pursuant to stock
options granted under the Equity Incentive Plan and (b) the
number of shares of restricted common stock awarded under the
Equity Incentive Plan to
13
(1) each of the Companys executive officers who are
named in the Summary Compensation Information table,
(2) all current executive officers as a group, (3) all
current directors who are not executive officers as a group, and
(4) all employees who are not executive officers as a
group. There is no separate disclosure with respect to director
nominees, because all of them currently are directors of the
Company whose information is already shown in the table.
|
|
|
|
|
|
|
|
|
|
|
|
Restricted Shares | |
|
Option Shares | |
Name or Category |
|
Granted | |
|
Granted | |
|
|
| |
|
| |
Edward K. Aldag, Jr.
|
|
|
217,805 |
|
|
|
|
|
|
Chairman of the Board, Chief Executive Officer and President |
|
|
|
|
|
|
|
|
Emmett E. McLean
|
|
|
93,815 |
|
|
|
|
|
|
Executive Vice President, Chief Operating Officer, Treasurer and
Assistant Secretary |
|
|
|
|
|
|
|
|
R. Steven Hamner
|
|
|
125,218 |
|
|
|
|
|
|
Director, Executive Vice President and Chief Financial Officer |
|
|
|
|
|
|
|
|
William G. McKenzie
|
|
|
52,342 |
|
|
|
|
|
|
Vice Chairman of the Board |
|
|
|
|
|
|
|
|
Michael G. Stewart
|
|
|
50,000 |
|
|
|
|
|
|
Executive Vice President, General Counsel and Secretary |
|
|
|
|
|
|
|
|
All current executive officers as a group
|
|
|
539,180 |
|
|
|
|
|
All current directors who are not executive officers as a group
|
|
|
87,500 |
|
|
|
112,500 |
(1) |
All employees who are not executive officers as a group
|
|
|
52,000 |
|
|
|
|
|
|
|
(1) |
Includes 12,500 shares issuable upon conversion of deferred
stock units. |
Future Award Grants. The granting of
equity-based awards under the Equity Incentive Plan is at the
discretion of the Compensation Committee. The Compensation
Committee has determined that, at the time of each annual
meeting of stockholders following his or her election to the
Board of Directors, each independent director is to receive
2,000 shares of common stock, restricted as to transfer for
three years, or a comparable number of deferred stock units. The
Compensation Committee may change the compensation of the
Companys independent directors in its discretion. The
Compensation Committee has not yet determined any other awards
that will be granted under the Equity Incentive Plan, as it is
proposed to be amended, to the persons and groups of persons
identified in the preceding table. In addition, if the Equity
Incentive Plan, amended as herein described, had been in effect
in 2004, such persons and groups of persons would not have
received awards that were any different in type or amount than
those that they actually received in 2004.
Board
of Directors Recommendation
BASED ON THE RECOMMENDATION OF THE COMPENSATION COMMITTEE AND
OUR REVIEW OF THAT REQUEST, THE BOARD OF DIRECTORS BELIEVES IT
IS IN THE BEST INTEREST OF THE COMPANY TO RECOMMEND THAT YOU
VOTE FOR THE APPROVAL OF THE AMENDMENT OF THE EQUITY
INCENTIVE PLAN TO INCREASE FROM 2,052 BY 3,900,000 THE NUMBER OF
SHARES OF COMMON STOCK AVAILABLE FOR FUTURE AWARDS
THEREUNDER.
14
STOCK OWNERSHIP
Directors,
Executive Officers, and Other Stockholders
The following table provides information about the beneficial
ownership of the Companys common stock as of
August 31, 2005, unless otherwise indicated, by each
director of the Company, each executive officer of the Company
named in the Summary Compensation Information table
in this Proxy Statement, all directors and executive officers of
the Company as a group, and each person known to management of
the Company to be the beneficial owner of more than 5% of the
outstanding shares of common stock.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of | |
|
|
Number of Shares | |
|
Shares | |
Name of Beneficial Owner |
|
Beneficially Owned | |
|
Outstanding(1) | |
|
|
| |
|
| |
Directors and Executive Officers:
|
|
|
|
|
|
|
|
|
|
Edward K. Aldag, Jr.
|
|
|
499,022 |
(2) |
|
|
1.25 |
% |
|
Emmett E. McLean
|
|
|
199,022 |
(3) |
|
|
* |
|
|
R. Steven Hamner
|
|
|
199,022 |
(4) |
|
|
* |
|
|
William G. McKenzie
|
|
|
150,022 |
(5) |
|
|
* |
|
|
Michael G. Stewart
|
|
|
50,000 |
(6) |
|
|
* |
|
|
Virginia A. Clarke
|
|
|
24,166 |
(7) |
|
|
* |
|
|
G. Steven Dawson
|
|
|
50,833 |
(8) |
|
|
* |
|
|
Bryan L. Goolsby
|
|
|
24,166 |
(7) |
|
|
* |
|
|
Robert E. Holmes, Ph.D.
|
|
|
31,833 |
(8) |
|
|
* |
|
|
L. Glenn Orr, Jr.
|
|
|
24,166 |
(7) |
|
|
* |
|
|
All directors and executive officers as a group (10 persons)
|
|
|
1,300,752 |
(9) |
|
|
3.25 |
% |
Other Stockholders:
|
|
|
|
|
|
|
|
|
|
Friedman Billings Ramsey Group, Inc.
|
|
|
2,842,762 |
(10) |
|
|
7.11 |
% |
|
|
466 Lexington Avenue |
|
|
|
|
|
|
|
|
|
|
New York, New York 10017 |
|
|
|
|
|
|
|
|
|
Jeffrey L. Feinberg
|
|
|
2,399,300 |
(11) |
|
|
6.00 |
% |
|
|
c/o JLF Asset Management, L.L.C |
|
|
|
|
|
|
|
|
|
|
2775 Via de la Valle, Suite 204 |
|
|
|
|
|
|
|
|
|
|
Del Mar, CA 92014 |
|
|
|
|
|
|
|
|
|
|
|
|
* |
Less than 1% of the outstanding shares of common stock. |
|
|
|
|
(1) |
Based on 39,969,065 shares of common stock outstanding as
of August 31, 2005. Shares of common stock that are deemed
to be beneficially owned by a stockholder within 60 days
after August 31, 2005 are deemed outstanding for purposes
of computing such stockholders percentage ownership but
are not deemed outstanding for the purpose of computing the
percentage outstanding of any other stockholder. Except as
otherwise indicated in the notes to this table, beneficial
ownership includes sole voting and investment power. |
|
|
(2) |
Includes 217,805 shares of restricted common stock. |
|
|
(3) |
Includes 93,815 shares of restricted common stock. |
|
|
(4) |
Includes 125,218 shares of restricted common stock. |
|
|
(5) |
Includes 52,342 shares of restricted common stock. |
|
|
(6) |
Includes 50,000 shares of restricted common stock. |
|
|
(7) |
Includes 6,666 shares of common stock issuable upon
exercise of a vested stock option and 17,500 shares of
restricted common stock. |
|
|
(8) |
Includes 13,333 shares of common stock issuable upon
exercise of a vested stock option and 17,500 shares of
restricted common stock. |
15
|
|
|
|
(9) |
See notes (1) - (8) above. |
|
|
|
(10) |
Includes 1,795,571 shares of common stock owned directly by
Friedman, Billings, Ramsey Group, Inc., the parent company of
Friedman, Billings, Ramsey & Co., Inc.,
52,191 shares owned directly by Friedman, Billings,
Ramsey & Co., Inc., and 995,000 shares held by
various investment funds over which Friedman, Billings, Ramsey
Group, Inc., through a wholly-owned indirect subsidiary,
exercises shared investment and voting power. |
|
|
(11) |
Based on Schedule 13G, filed July 25, 2005. Includes
shares of common stock held by Jeffrey L. Feinberg,
individually, JLF Partners I, L.P., JLF Partners II,
L.P. and JLF Offshore Fund, Ltd. to which JLF Asset Management,
L.L.C. serves as the management company and/or investment
manager. Jeffrey L. Feinberg is the managing member of JLF Asset
Management, L.L.C. Jeffrey L. Feinberg and JLF Asset Management,
L.L.C. share voting power over these shares. |
Section 16(a) Beneficial
Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934
requires that the Companys directors and executive
officers and the beneficial owners of more than 10% of the
Companys equity securities (the reporting
persons) file with the Securities and Exchange Commission
(the SEC) initial reports of, and subsequent reports
of changes in, their beneficial ownership of the Companys
equity securities. Because the Company did not have equity
securities registered under Section 12 of the Securities
Exchange Act of 1934 until July 2005, it was not required to
comply with Section 16(a) during 2004.
Certain
Transactions
On March 31, 2004, we entered into a Purchase/ Placement
Agreement with Friedman, Billings, Ramsey & Co., Inc.,
pursuant to which Friedman, Billings, Ramsey & Co.,
Inc. acted as initial purchaser and sole placement agent for our
April 2004 private placement and received aggregate initial
purchaser discounts and placement fees of $17.7 million. In
addition, we issued 260,954 shares of our common stock to
Friedman, Billings, Ramsey & Co., Inc. as payment for
financial advisory services. On July 13, 2005, we completed
an initial public offering of 12,066,823 shares of common
stock, priced at $10.50 per share. Of these shares of
common stock, 701,823 shares were sold by selling
stockholders and 11,365,000 shares were sold by us.
Friedman, Billings, Ramsey & Co., Inc. served as the
sole book-running manager for the offering. In connection with
the initial public offering, Friedman, Billings,
Ramsey & Co., Inc. received underwriting discounts,
commissions, and other fees from us in the amount of $8,353,275.
As of July 15, 2005, Friedman Billings Ramsey Group, Inc.,
an affiliate of Friedman, Billings, Ramsey & Co., Inc.,
beneficially owned, directly or indirectly, through affiliates,
2,868,857 shares of our common stock or approximately 7.18%
of our outstanding common stock. We have an account with
Friedman, Billings, Ramsey & Co., Inc. through which we
manage approximately $141.7 of our cash and cash equivalents as
of July 15, 2005.
In December 2004 and January 2005, the law firm of Locke,
Liddell & Sapp LLP, of which Mr. Goolsby is a
partner, provided certain legal services to the Companys
Ethics, Nominating and Corporate Governance Committee.
INDEPENDENT AUDITOR
The Audit Committee of the Board of Directors has selected KPMG
LLP as the independent auditor to perform the audit of the
Companys consolidated financial statements for 2005. KPMG
has audited the Companys consolidated financial statements
since 2003. KPMG is a registered public accounting firm.
Representatives of KPMG are expected to be present at the
meeting. They will have an opportunity to make a statement if
they so desire and will be available to respond to appropriate
questions from the Companys stockholders.
16
Audit
and Non-Audit Services
The Audit Committee is directly responsible for the appointment,
compensation, and oversight of the Companys independent
auditor. In addition to retaining KPMG to audit the
Companys consolidated financial statements for 2004, the
Audit Committee retained KPMG to provide other auditing and
advisory services in 2004. The Audit Committee understands the
need for KPMG to maintain objectivity and independence in its
audits of the Companys financial statements. The Audit
Committee has reviewed all non-audit services provided by KPMG
in 2004 and has concluded that the provision of such services
was compatible with maintaining KPMGs independence in the
conduct of its auditing functions.
To help ensure the independence of the independent auditor, the
Audit Committee has adopted a policy for the pre-approval of all
audit and non-audit services to be performed for the Company by
its independent auditor. Pursuant to this policy, all audit and
non-audit services to be performed by the independent auditor
must be approved in advance by the Audit Committee.
The table below sets forth the aggregate fees billed by KPMG for
audit and non-audit services provided to the Company in 2004 and
2003.
|
|
|
|
|
|
|
|
|
|
Fees |
|
2004 | |
|
2003 | |
|
|
| |
|
| |
Audit Fees
|
|
$ |
340,598 |
|
|
$ |
85,000 |
|
Audit-Related Fees
|
|
|
223,758 |
|
|
|
0 |
|
Tax Fees:
|
|
|
|
|
|
|
|
|
|
Tax Compliance Fees
|
|
|
0 |
|
|
|
0 |
|
|
All Other Tax Fees
|
|
|
3,000 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
Total Tax Fees
|
|
|
3,000 |
|
|
|
0 |
|
All Other Fees
|
|
|
0 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
567,356 |
|
|
$ |
85,000 |
|
|
|
|
|
|
|
|
In the above table, in accordance with the SECs
definitions and rules, audit fees are fees for
professional services for the audit of a companys annual
financial statements, for the review of a companys
quarterly financial statements and for services that are
normally provided by the accountant in connection with statutory
and regulatory filings or engagements; audit-related
fees are fees for assurance and related services that are
reasonably related to the performance of the audit or review of
a companys financial statements; tax fees are
fees for tax compliance, tax advice and tax planning; and
all other fees are fees for any services not
included in the first three categories.
Audit
Committee Report
Management is responsible for the Companys accounting and
financial reporting processes, including its internal control
over financial reporting, and for preparing the Companys
consolidated financial statements. KPMG LLP, the Companys
independent auditor, is responsible for performing an audit of
the Companys consolidated financial statements in
accordance with the standards of the Public Company Accounting
Oversight Board and for expressing an opinion on the conformity
of the Companys audited consolidated financial statements
to accounting principles generally accepted in the United States
of America. In this context, the responsibility of the Audit
Committee of the Board of Directors is to oversee the
Companys accounting and financial reporting processes and
the audits of its consolidated financial statements.
In the performance of its oversight function, the Audit
Committee reviewed and discussed with management and KPMG the
Companys audited consolidated financial statements as of
and for the year ended December 31, 2004. Management and
KPMG represented to the Audit Committee that the Companys
audited consolidated financial statements as of and for the year
ended December 31, 2004, were prepared in accordance with
accounting principles generally accepted in the United States of
America. The Audit Committee also discussed with KPMG the
matters required to be discussed by Statement on Auditing
17
Standards Nos. 61, 89 and 90 issued by the Auditing Standards
Board of the American Institute of Certified Public Accountants.
SAS Nos. 61, 89 and 90 set forth requirements pertaining to the
independent auditors communications with the Audit
Committee regarding the conduct of the audit.
The Audit Committee received the written disclosures and the
letter from KPMG required by Independence Standards Board
Standard No. 1, Independence Discussions with Audit
Committees, as amended. ISB Standard No. 1 requires the
independent auditor to disclose in writing to the Audit
Committee all relationships between the auditor and the Company
that, in the auditors judgment, reasonably may be thought
to bear on independence and to discuss the auditors
independence with the Audit Committee. The Audit Committee
discussed with KPMG its independence and considered in advance
whether the provision of any non-audit services by KPMG is
compatible with maintaining their independence.
The members of the Audit Committee are not professionally
engaged in the practice of accounting or auditing and, as such,
rely without independent verification on the information
provided to them and on the representations made by management
and KPMG. Accordingly, the Audit Committees oversight does
not provide an independent basis to determine that management
has maintained appropriate accounting and financial reporting
processes or appropriate internal controls and procedures
designed to assure compliance with the accounting standards and
applicable laws and regulations. Furthermore, the Audit
Committees reviews and discussions referred to above do
not assure that the audit of the Companys financial
statements has been carried out in accordance with generally
accepted auditing standards, that the Companys audited
consolidated financial statements are presented in accordance
with generally accepted accounting principles, or that KPMG is
in fact independent.
The Company was not required to file an Annual Report on
Form 10-K for the year ended December 31, 2004.
The foregoing report is provided by the undersigned members of
the Audit Committee of the Board of Directors.
* * *
|
|
|
G. Steven Dawson (Chairman) |
|
Virginia A. Clarke |
|
L. Glenn Orr, Jr. |
EXECUTIVE OFFICERS AND EXECUTIVE COMPENSATION
Executive
Officers and Other Senior Management
For information regarding Mr. Aldag, Mr. Hamner and
Mr. McKenzie, please see Proposal 1
Election of Directors above.
Emmett E. McLean. Emmett E. McLean, age 50, is
one of our founders and has served as our Executive Vice
President, Chief Operating Officer and Treasurer since September
2003. Mr. McLean has served as Assistant Secretary since
April 2004. In August and September 2004, Mr. McLean also
served as our Chief Financial Officer. Mr. McLean was one
of our directors from September 2003 until April 2004. From June
to September, 2003, Mr. McLean served as Executive Vice
President, Chief Financial Officer, and Treasurer and board
member of our predecessor. From 2000 to 2003, Mr. McLean
was a private investor and, for part of that period, served as a
consultant to a privately held company. From 1995 to 2000,
Mr. McLean served as Senior Vice President
Development, Secretary, Treasurer and a board member of
PsychPartners, L.L.C., a healthcare services and practice
management company. Prior to 1992, Mr. McLean worked in the
investment banking field. Mr. McLean received an MBA from
the University of Virginia and a B.A. in Economics from The
University of North Carolina.
Michael G. Stewart. Michael G. Stewart, age 50,
has served as our General Counsel since October 2004 and as our
Executive Vice President and Secretary since March 2005. Prior
to October 2004,
18
Mr. Stewart worked as a private investor, healthcare
consultant and novelist. He advised physician and surgery groups
on emerging healthcare issues for four years before publishing
three novels. From 1993 until 1995, he served as Vice President
and General Counsel of Complete Health Services, Inc., a managed
care company, and its successor corporation, United Healthcare
of the South, a division of United Healthcare, Inc. (NYSE: UNH).
Mr. Stewart was engaged in the private practice of law
between 1988 and 1993. Mr. Stewart holds a J.D. degree from
Cumberland School of Law of Samford University and a B.S. in
Business Administration from Auburn University.
Summary Compensation Information
The table below sets forth summary compensation information for
the Companys Chief Executive Officer in 2004 and for each
of the four other most highly compensated executive officers of
the Company who were serving in such capacities on
December 31, 2004.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual Compensation | |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
Other Annual | |
|
All Other | |
Name and Principal Positions |
|
Year | |
|
Salary | |
|
Bonus | |
|
Compensation | |
|
Compensation | |
|
|
| |
|
| |
|
| |
|
| |
|
| |
Edward K. Aldag, Jr.
|
|
|
2004 |
|
|
$ |
350,000 |
|
|
$ |
350,000 |
|
|
$ |
50,462 |
(1) |
|
$ |
30,769 |
(2) |
|
Chairman of the Board, Chief Executive |
|
|
2003 |
|
|
|
145,833 |
(3) |
|
|
145,833 |
|
|
|
10,492 |
(4) |
|
|
9,249 |
(5) |
|
Officer and President |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Emmett E. McLean
|
|
|
2004 |
|
|
|
250,000 |
|
|
|
250,000 |
|
|
$ |
24,385 |
(6) |
|
|
15,385 |
(2) |
|
Executive Vice President, Chief Operating |
|
|
2003 |
|
|
|
104,167 |
(3) |
|
|
104,167 |
|
|
|
|
|
|
|
10,896 |
(7) |
|
Officer, Treasurer and Assistant Secretary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
R. Steven Hamner
|
|
|
2004 |
|
|
|
250,000 |
|
|
|
250,000 |
|
|
$ |
24,385 |
(6) |
|
|
15,385 |
(2) |
|
Director, Executive Vice President and |
|
|
2003 |
|
|
|
104,167 |
(3) |
|
|
104,167 |
|
|
|
|
|
|
|
5,918 |
(8) |
|
Chief Financial Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
William G. McKenzie
|
|
|
2004 |
|
|
|
175,000 |
|
|
|
175,000 |
|
|
|
|
|
|
|
|
|
|
Vice Chairman of the Board |
|
|
2003 |
|
|
|
72,917 |
(3) |
|
|
72,917 |
|
|
|
|
|
|
|
|
|
Michael G. Stewart
|
|
|
2004 |
|
|
|
43,527 |
(9) |
|
|
42,188 |
|
|
|
|
|
|
|
1,700 |
|
|
Executive Vice President, General Counsel |
|
|
2003 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
and Secretary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Represents a $12,000 automobile allowance and $25,000 payable to
Mr. Aldag to reimburse him for the cost of tax preparation
and financial planning services and $13,462 to reimburse
Mr. Aldag for his tax liabilities associated with such
payment. |
|
(2) |
Represents reimbursement for life insurance premiums of $20,000
for Mr. Aldag and $10,000 for each of Messrs. McLean
and Hamner and reimbursement of $10,769 for Mr. Aldag and
$5,385 for each of Messrs. McLean and Hamner for tax
liabilities associated with such premium reimbursements. |
|
(3) |
For the partial year period from our inception in August 2003
until December 31, 2003. |
|
(4) |
Represents a $7,000 automobile allowance and $3,492 payable to
Mr. Aldag to reimburse him for the cost of tax preparation
and financial planning services. |
|
(5) |
Represents reimbursement for life insurance premiums of $9,249. |
|
(6) |
Represents a $9,000 automobile allowance and $10,000 for the
named executive officers to reimburse them for the cost of tax
preparation services and $5,385 for the named executive officers
to reimburse them for their tax liabilities associated with such
tax preparation cost reimbursement. |
|
(7) |
Represents reimbursement for life insurance premiums of $10,896. |
|
(8) |
Represents reimbursement for life insurance premiums of $5,918. |
|
(9) |
For the partial year period from October 25, 2004,
Mr. Stewarts date of hire, to December 31, 2004.
Had Mr. Stewart been employed for the full year 2004, he
would have been entitled to a base salary of $225,000 during
2004. Mr. Stewarts employment agreement was amended
effective April 28, 2005. His amended employment agreement
provides for an annual base salary of $250,000. |
Equity
Compensation Plan Information
The table below sets forth information regarding the shares of
common stock to be issued upon the exercise of the outstanding
options, warrants, and rights granted under the Companys
equity compensation plans and the shares of common stock
remaining available for future issuance under the Companys
equity
19
compensation plans as of December 31, 2004. The Company
does not have any outstanding warrants or other rights to
purchase shares of common stock pursuant to its equity
compensation plans.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Securities | |
|
|
Shares of Common Stock | |
|
Weighted-Average | |
|
Remaining | |
|
|
to be Issued upon Exercise | |
|
Exercise Price of | |
|
Available for Future | |
|
|
of Outstanding Options, | |
|
Outstanding Options, | |
|
Issuance under Equity | |
Plan Category |
|
Warrants and Rights | |
|
Warrants and Rights | |
|
Compensation Plans | |
|
|
| |
|
| |
|
| |
Equity compensation plans approved by security holders
|
|
|
112,500 |
(1) |
|
$ |
10.00 |
|
|
|
678,680 |
(2) |
Equity compensation plans not approved by security holders
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
Total
|
|
|
112,500 |
|
|
$ |
10.00 |
|
|
|
678,680 |
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Includes 12,500 deferred stock units and stock options for
100,000 shares of common stock granted solely to the
Companys independent directors. |
|
(2) |
Includes 106,000 shares of restricted common stock that
were approved by the Compensation Committee in 2004 for issuance
immediately following the closing of the Companys initial
public offering which occurred on July 13, 2005. |
The Companys stockholders have approved the Equity
Incentive Plan.
Employment
Agreements
We have employment agreements with each of the named executive
officers. These employment agreements provide the following
annual base salaries: Edward K. Aldag, Jr., $350,000;
Emmett E. McLean, $250,000; R. Steven Hamner,
$250,000; Michael G. Stewart, $250,000; and William G.
McKenzie, $175,000. On each January 1 hereafter, each of
the executive officers is to receive a minimum increase in his
base salary equal to the increase in the Consumer Price Index.
These agreements provide that the executive officers, other than
Mr. McKenzie, agree to devote substantially all of their
business time to our operation. The employment agreement for
each of the named executive officers is for a three-year term
which is automatically extended at the end of each year within
such term for an additional one year period, unless either party
gives notice of non-renewal as provided in the agreement. These
employment agreements permit us to terminate each
executives employment with appropriate notice for or
without cause.
Each of the named executive officers has the right under his
employment agreement to resign for good reason,
which includes (i) the employment agreement is not
automatically renewed by the Company; (ii) the termination
of certain incentive compensation programs; (iii) the
termination or diminution of certain employee benefit plans,
programs or material fringe benefits (other than for
Mr. McKenzie); (iv) the relocation of our principal
office outside of a 100 mile radius of Birmingham, Alabama
(in the case of Mr. Aldag); or (v) our breach of the
employment agreement which continues uncured for 30 days.
In addition, in the case of Mr. Aldag, the following
constitute good reason: (i) his removal from the Board of
Directors without cause or his failure to be nominated or
elected to the Board of Directors; or (ii) any material
reduction in duties, responsibilities or reporting requirements,
or the assignment of any duties, responsibilities or reporting
requirements that are inconsistent with his positions with us.
The executive employment agreements provide a monthly car
allowance of $1,000 for Mr. Aldag and $750 for each of
Messrs. McLean, Hamner and Stewart. Messrs. Aldag,
McLean, Hamner and Stewart are also reimbursed for the cost of
tax preparation and financial planning services, up to $25,000
annually for Mr. Aldag and $10,000 annually for each of
Messrs. McLean, Hamner and Stewart. We also reimburse each
executive for the income tax he incurs on the receipt of these
tax preparation and financial planning services. In addition,
the employment agreements provide for annual paid vacation of
six weeks for Mr. Aldag and three weeks for
Messrs. McLean, Hamner and Stewart and various other
customary benefits. The employment agreements also provide that
Mr. Aldag will receive up to $20,000 per year in
reimbursement for life insurance premiums, which amount is to
increase annually based on the increase in the Consumer Price
Index for such year, and that Messrs. McLean, Hamner and
Stewart will receive up to $10,000 per year in
reimbursement for life insurance premiums which amount is to
increase annually based on the increase in the Consumer Price
20
Index for such year. We also reimburse each executive for the
income tax he incurs on the receipt of these premium
reimbursements.
The employment agreements referred to above provide that the
executive officers are eligible to receive the same benefits,
including medical insurance coverage and retirement plan
benefits in a 401(k) plan to the same extent as other similarly
situated employees, and such other benefits as are commensurate
with their position. Participation in employee benefit plans is
subject to the terms of said benefit plans as in effect from
time to time.
If the named executive officers employment ends for any
reason, we will pay accrued salary, bonuses and incentive
payments already determined, and other existing obligations. In
addition, if we terminate the named executive officers
employment without cause or if any of them terminates his
employment for good reason, we will be obligated to pay
(i) a lump sum payment of severance equal to the sum of
(x) the product of three and the sum of the salary in
effect at the time of termination plus the average cash bonus
(or the highest cash bonus, in the case of Mr. Aldag) paid
to such executive during the preceding three years, grossed up
for taxes in the case of Mr. Aldag, and (y) the
incentive bonus prorated for the year in which the termination
occurred, (ii) other than for Mr. McKenzie, the cost
of the executives continued participation in the
companys benefit and welfare plans (other than the 401(k)
plan) for a three year period (or for a five year period in the
case of Mr. Aldag), and (iii) certain other benefits
as provided for in the employment agreement. Additionally, in
the event of a termination by us for any reason other than cause
or by the executive for good reason, all of the options and
restricted stock granted to the executive will become fully
vested, and the executive will have whatever period remains
under the options in which to exercise all vested options.
In the event of a termination of the employment of our
executives as a result of death, then in addition to the accrued
salary, bonus and incentive payments due to them, they shall
become fully vested in their options and restricted stock, and
their respective beneficiaries will have whatever period remains
under the options to exercise such options. In addition, the
executives would be entitled to their prorated incentive bonuses.
In the event the employment of our executives ends as a result
of a termination by us for cause or by the executives without
good reason, then in addition to the accrued salary, bonuses and
incentive payments due to them, the executives would be entitled
to exercise their vested stock options pursuant to the terms of
the grant, but all other unvested options and restricted stock
would be forfeited.
Upon a change of control, the named executive officers will
become fully vested in their options and restricted stock and
will have whatever period remains under the option in which to
exercise their options. In addition, if any executives
employment is terminated by us for cause or by the executive
without good reason in connection with a change of control, the
executive will be entitled to receive an amount equal to the
largest cash compensation paid to the executive for any twelve
month period during his tenure multiplied by three.
If payments become due as a result of a change in control and
the excise tax imposed by Code Section 4999 applies, the
terms of the employment agreements require us to gross up the
amount payable to the executive by the amount of this excise tax
plus the amount of income and other taxes due as a result of the
gross up payment.
For an 18 month period after termination of an
executives employment for any reason other than
(i) termination by us without cause or
(ii) termination by the executive for good reason, each of
the executives under these employment agreements has agreed not
to compete with us by working with or investing in, subject to
certain limited exceptions, any enterprise engaged in a business
substantially similar to our business as it was conducted during
the period of the executives employment with us.
The employment agreements provide that these named executive
officers are eligible to participate in our equity
incentive plan. The employment agreements also provide
that the named executive officers are eligible to receive annual
cash bonuses under our bonus policy in an amount not less than
40% and not more than 100% of their base salary based on the
bonus policy adopted by the Compensation Committee.
21
Compensation
Committee Report
Overview. A principal function of the Compensation
Committee is to review and approve the Companys executive
compensation program. The compensation program is designed to
attract and retain high caliber executives, to maintain a
performance oriented environment, and to align the interests of
the Companys executives with the interests of its
stockholders. In seeking to maximize achievement and
productivity, the executive compensation program focuses on
three elements: base salaries, annual incentive awards, and
long-term incentives that are tied to Company performance.
Base Salary. The Company has employment agreements
with each of the named executive officers. The employment
agreements provide for an initial base salary that is subject to
annual increases following the Compensation Committees
evaluation of each executives performance, the
executives level of responsibility, and the performance of
the Company as a whole. The Compensation Committee also
considers the success of the executive officer in developing and
executing the Companys strategic plan, as well as each
executives success in exercising leadership and creating
stockholder value. Moreover, the Compensation Committee
researches the latest survey information available to confirm
appropriate compensation levels.
Annual Incentive Bonus. Our employment agreements
with each of the named executive officers provide for annual
incentive bonuses. Pursuant to those employment agreements, each
executive officers annual incentive bonus is calculated as
a percentage of his or her base salary, with the percentage
being set by the Compensation Committee in the range of 40% to
100% of base salary. As a result of the performance in 2004 of
the Company and each of the individual executive officers, the
executives received incentive bonuses equal to 100% of their
base salaries. The total amount of incentive bonuses paid to the
executive officers in 2004 was $1,067,188.
Long-Term Incentive Awards. The Company may grant
long-term, equity-based incentive awards to its executive
officers under the Amended and Restated Medical Properties
Trust, Inc. 2004 Equity Incentive Plan. Under the Equity
Incentive Plan, which is administered by the Compensation
Committee, the Company may grant long-term, equity-based awards
in the form of incentive stock options, nonqualified stock
options, restricted common stock, restricted stock units,
deferred stock units, stock appreciation rights and performance
share units. Based on an assessment of competitive factors and
performance, the Compensation Committee determines an award that
is sufficient to both properly reward, and provide future
incentive for, each executive officer.
To closely align the interests of the executive officers with
those of our stockholders, the Compensation Committees
practice has been to make incentive awards in the form of
restricted common stock. In 2004, the Compensation Committee
approved the award of 106,000 shares of restricted common
stock to the executive officers to be effective on the first
business day following the closing of the Companys initial
public offering. To encourage retention, the restricted common
stock generally vests over a period of several years. The
restricted common stock awarded to the executive officers in
2004 vests at the rate of 8.33% per quarter beginning on
September 30, 2005 and the last day of each calendar
quarter thereafter until fully vested.
Compensation of Chief Executive Officer. Edward K.
Aldag, Jr. served as the Companys Chairman of the
Board, Chief Executive Officer, and President in 2004 and
continues to hold those offices. Mr. Aldag has an
employment agreement with the Company covering his service as
its President and Chief Executor Officer. Pursuant to the
agreement, the Company paid Mr. Aldag a base salary of
$350,000 during 2004. Mr. Aldag also was eligible under the
Companys annual incentive bonus plan to receive an
incentive bonus, calculated as a percentage of his base salary,
in the event that the Company achieved certain performance
objectives. Mr. Aldags target bonus percentage was
40% to 100% of his base salary. Based on the Compensation
Committees review and assessment of his and the
Companys performance in 2004, Mr. Aldag received an
annual incentive bonus for 2004 in the amount of $350,000, or
100% of his base salary. The Compensation
22
Committee considers the total compensation received by
Mr. Aldag for 2004 to be both reasonable and appropriate.
* * *
|
|
|
L. Glenn Orr, Jr. (Chairman) |
|
G. Steven Dawson |
|
Bryan L. Goolsby |
Compensation
Committee Interlocks and Insider Participation
No member of the Compensation Committee during 2004 is or was an
officer or employee of the Company or any of its subsidiaries.
In addition, no executive officer of the Company served during
2004 as a director or a member of the compensation committee of
any entity that had an executive officer serving as a director
of the Company or a member of the Compensation Committee of the
Board of Directors.
OTHER MATTERS
As of the date hereof, the Board of Directors knows of no
business that will be presented at the meeting other than the
proposals described in this Proxy Statement. If any other
proposal properly comes before the stockholders for a vote at
the meeting, the proxy holders will vote the shares of common
stock represented by proxies that are submitted to the Company
in accordance with their best judgment.
ADDITIONAL INFORMATION
Solicitation
of Proxies
The Company will solicit proxies on behalf of the Board of
Directors by mail, telephone, facsimile or other electronic
means or in person. The Company will pay the proxy solicitation
costs. The Company has engaged Innisfree M&A, Incorporated
to assist in soliciting proxies for a fee of $9,000, plus the
reimbursement of its reasonable out-of-pocket expenses. The
Company will supply copies of the proxy solicitation materials
to brokerage firms, banks, and other nominees for the purpose of
soliciting proxies from the beneficial owners of the shares of
common stock held of record by such nominees. The Company
requests that such brokerage firms, banks, and other nominees
forward the proxy solicitation materials to the beneficial
owners and will reimburse them for their reasonable expenses.
Stockholder Proposals for Inclusion in Proxy Statement for 2006
Annual Meeting of Stockholders
To be considered for inclusion in the Companys proxy
statement for the 2006 annual meeting of stockholders, a
stockholder proposal must be received by the Company no later
than the close of business on December 16, 2005.
Stockholder proposals must be sent to Secretary, Medical
Properties Trust, Inc., 1000 Urban Center Drive,
Suite 501, Birmingham, Alabama 35242. The Company will not
be required to include in its proxy statement any stockholder
proposal that does not meet all the requirements for such
inclusion established by the SECs proxy rules and Maryland
corporate law.
Other
Stockholder Proposals
The Companys Amended and Restated Bylaws provide that a
stockholder who desires to propose any business at an annual
meeting of stockholders must give the Company written notice of
such stockholders intent to bring such business before
such meeting. Such notice is to be delivered to, or mailed,
postage prepaid, and received by, the Secretary at Medical
Properties Trust, Inc., 1000 Urban Center Drive, Suite 501,
Birmingham, Alabama 35242 not less than 90 days nor more
than 120 days prior to the first anniversary of the
23
date of the mailing of the notice for the preceding years
annual meeting. However, in the event that the date of the
annual meeting is more than 30 days before or more than
60 days after the anniversary date of the preceding
years annual meeting, notice by the stockholder to be
timely must be so delivered not earlier than 120 days prior
to such annual meeting and not later than the later of
60 days prior to such annual meeting and 10 days
following the issuance by the Corporation of a press release
announcing the meeting date. The stockholders written
notice must set forth a brief description of the business
desired to be brought before the meeting and certain other
information as set forth in Section 1.02 of the
Companys Amended and Restated Bylaws. Stockholders may
obtain a copy of our Amended and Restated Bylaws by writing to
our Secretary at the address shown above.
Stockholder
Nominations of Directors
The Companys Amended and Restated Bylaws provide that a
stockholder who desires to nominate directors at a meeting of
stockholders must give the Company written notice, within the
same time period described above for a stockholder who desires
to bring business before a meeting. Notice of a nomination must
be delivered to, or mailed and received at, Medical Properties
Trust, Inc., 1000 Urban Center Drive, Suite 501,
Birmingham, Alabama 35242, Attention Secretary. As set forth in
Section 2.03 of our Amended and Restated Bylaws, the notice
must set forth certain information as to each person whom the
stockholder proposes to nominate for election or re-election as
a director and as to the stockholder giving the notice.
|
|
|
By Order of the Board of Directors, |
|
|
|
|
|
Michael G. Stewart |
|
Secretary |
Birmingham, Alabama
September 13, 2005
24
APPENDIX A
MEDICAL PROPERTIES TRUST, INC.
CHARTER OF THE AUDIT COMMITTEE
PURPOSE
|
|
|
The Audit Committee (the Committee) will assist the
Board of Directors (the Board) of Medical Properties
Trust, Inc. (the Company) in fulfilling its
oversight responsibilities including accounting and financial
reporting processes, integrity and audits of financial
statements, compliance with legal and regulatory requirements,
qualifications and independence of the independent auditors, and
performance of internal and independent auditors. The Committee
will oversee the Companys accounting and financial
reporting process, and the audits of its financial statements,
and will assist the Board in monitoring the integrity of the
Companys financial statements, the independent auditors
qualifications and independence, the performance of the
Companys internal audit function, and the Companys
compliance with laws and regulations and with the Code of Ethics
and Business Conduct. |
MEMBERSHIP
|
|
|
The Committee shall be composed of three or more members of the
Board of the Company, who shall meet the independence and
experience requirements of the New York Stock Exchange,
Section 10A(m)(3) of the Securities Exchange Act of 1934
(the Exchange Act) and the rules and regulations of
the Securities and Exchange Commission (the
Commission). No member may serve on more than three
public company audit committees unless the Board determines that
such service will not impair that members ability to
effectively serve on the Committee. |
|
|
At least one member shall be an audit committee financial expert
in accordance with the rules of the Commission, and at least one
member (who may also serve as the audit committee financial
expert) shall have accounting or related financial management
expertise. All other members shall be financially literate. To
effectively perform his or her role, each Committee member will
obtain an understanding of the detailed responsibilities of
Committee membership as well as the Companys business,
operations and risks. Members shall be appointed by the Board on
the recommendation of the Ethics, Nominating and Corporate
Governance Committee. Members may be replaced by the Board. |
MEETINGS
|
|
|
The Committee shall meet at least quarterly, but it may be
appropriate to meet more frequently. The Committee shall set
aside a portion of each regular quarterly meeting to meet with
the senior executive officers, the internal audit staff and the
independent auditors in separate executive sessions. The
Committee may request any officer or employee of the Company or
the Companys outside counsel or independent auditor to
attend a meeting of the Committee or to meet with any members
of, or consultants to, the Committee. A portion of each meeting
may be set aside for a private session with any officer or
employee of the Company, the Companys outside counsel or
independent auditor, or any consultant to the Committee. |
|
|
A meeting of the Committee may be called at any time by its
Chairman, without notice to or the consent of the Board or
management, for the purpose of discussing or reviewing matters
under its authority. |
DUTIES AND RESPONSIBILITIES
|
|
1. |
The Committee shall, in its capacity as a committee of the
Board, be directly responsible for the appointment,
compensation, retention and oversight of the work of the
independent auditor (including resolution of disagreements
between management and the independent auditor regarding
financial reporting) for the purpose of preparing or issuing an
audit report or related work. The independent auditor shall
report directly to the Committee. |
|
|
2. |
The Committee shall pre-approve all auditing services and
permitted non-audit services (including the fees and terms
thereof) to be performed for the Company by its independent
auditor, subject to the de minimis exceptions for non-audit
services described in Section 10A(i)(1)(B) of the Exchange
Act which are approved by the Committee prior to the completion
of the audit. The Committee shall meet with the independent
auditor prior to the audit to review the planning and staffing
of the audit. |
|
3. |
The Committee shall review and evaluate the lead partner of the
independent auditor team; evaluate the qualifications,
performance and independence of the independent auditor,
including whether the auditors quality controls are
adequate and whether the provision of permitted non-audit
services is compatible with maintaining the auditors
independence, and taking into account the opinions of management
and the internal auditor; and present its conclusions to the
Board. |
|
4. |
The Committee shall ensure that the lead audit partner and the
reviewing partner rotate, as required by law, and consider
whether there should be a regular rotation of the independent
auditing firm. |
|
5. |
The Committee shall discuss with management and independent
auditors significant financial reporting issues and judgments
made in connection with preparation of the Companys
financial statements, including significant changes in the
selection or application of accounting principles, major issues
as to the adequacy of internal controls, and any special steps
adopted in light of material control deficiencies. |
|
6. |
The Committee shall review with the independent auditor any
audit problems or difficulties and managements response.
Such review shall include any accounting adjustments that were
noted or proposed by the auditor but were passed (as
immaterial or otherwise); review any management or
internal control letters issued, or proposed to be
issued, by the independent auditor to the Company and any
discussions with the independent auditors national office
respecting auditing or accounting issues presented by the
engagement. |
|
7. |
The Committee shall review and discuss with management and the
independent auditors the annual audited financial statements and
quarterly financial statements, including the Companys
specific disclosures in Managements Discussion and
Analysis of Financial Condition and Results of Operations and
the results of the independent auditors reviews of the
quarterly financial statements, and recommend to the Board
whether the annual audited financial statements should be
included in any Form 10-K to be filed by the Company. |
|
8. |
The Committee shall discuss with management and the independent
auditor the effect of regulatory and accounting initiatives as
well as off-balance sheet structures on the Companys
financial statements. |
|
9. |
The Committee shall meet annually with the independent public
accountants to: |
|
|
|
|
|
Obtain and review a report from the independent auditor
regarding the independent auditors internal
quality-control procedures, any material issues raised by the
most recent internal quality-control or peer review of the firm,
or by any inquiry or investigation by governmental or
professional authorities within the preceding 5 years, any
steps taken to deal with any such issues, and all relationships
between the independent auditor and the Company. |
|
|
|
Review major changes to the Companys auditing and
accounting principles and practices as suggested by the
independent auditor, internal auditors or management. |
|
|
|
Discuss items which could provide a material risk to the Company
in the future. |
|
|
|
Obtain from the independent auditor assurance that
Section 10A of the Exchange Act has not been implicated. |
|
|
|
Discuss matters required to be discussed by Statement on
Auditing Standards No. 61 relating to the conduct of the
audit, and in particular: |
|
|
|
|
|
The auditors responsibility under generally accepted
auditing standards. |
|
|
Significant accounting policies. |
|
|
Management judgments and accounting estimates. |
A-2
|
|
|
|
|
Audit adjustments. |
|
|
Auditors judgments about the quality of the entitys
accounting principles. |
|
|
Other information in documents containing audited financial
statements. |
|
|
Disagreements with management. |
|
|
Consultation with other accountants. |
|
|
Major issues discussed with management prior to retention. |
|
|
Difficulties encountered in performing the audit. |
|
|
10. |
The Committee shall oversee the hiring of any independent audit
firm personnel into positions within the Company in accordance
with the hiring restrictions of the Sarbanes-Oxley Act. |
|
11. |
The Committee shall discuss with management and the independent
auditor the Companys earnings press releases, including
the use of pro forma or adjusted
non-GAAP information, as well as financial information and
earnings guidance provided to analyst and rating agencies. Such
discussion may be done generally (consisting of discussing the
types of information to be disclosed and the types of
presentations to be made). |
|
12. |
The Committee shall review and discuss any quarterly reports
from the independent auditors on: |
|
|
|
|
|
All critical accounting policies and practices to be used. |
|
|
|
All alternative treatments of financial information within
generally accepted accounting principles that have been
discussed with management, ramifications of the use of such
alternative disclosures and treatments, and the treatment
preferred by the independent auditor. |
|
|
|
Other material written communications between the independent
auditor and management, such as any management letter or
schedule of unadjusted differences. |
|
|
13. |
The Committee shall discuss with management and the independent
auditor any correspondence with regulators or governmental
agencies and any published reports that raise material issues
regarding the Companys financial statements or accounting
policies. |
|
14. |
The Committee shall establish procedures for (a) the
receipt, retention and treatment of complaints received by the
Company regarding accounting, internal accounting controls, or
auditing matters, and (b) the confidential, anonymous
submission by employees of concerns regarding questionable
accounting or auditing matters. |
|
15. |
The Committee shall review the appointment and replacement of
the director of the internal auditing department. |
|
16. |
The Committee shall review any significant matters contained in
reports prepared by the internal auditing department and meet
privately with the internal audit manager each quarter to
discuss concerns relating to internal controls or accounting and
auditing matters. |
|
17. |
The Committee shall meet with Company senior management
periodically to review: |
|
|
|
|
|
Major financial risk exposures. |
|
|
|
Material legal issues. |
|
|
|
Plans for disaster recovery. |
|
|
|
Risk Management activities. |
|
|
|
Business issues which may affect financial results. |
|
|
|
Ethical standards and conduct. |
|
|
|
Management Information Systems activities. |
A-3
|
|
18. |
The Company shall discuss with management the Companys
major financial risk exposure and the steps management has taken
to monitor and control such exposure, including the
Companys risk assessment and risk management policies. |
|
19. |
The Committee shall have the authority to retain, to the extent
it deems necessary or appropriate, independent legal, accounting
or other advisors. The Company shall provide for appropriate
funding, as determined by the Committee in its capacity as a
committee of the Board, for payment of compensation to the
independent auditor for the purpose of rendering or issuing an
audit report and to any advisors employed by the Committee, and
ordinary administrative expenses of the Committee that are
necessary or appropriate in carrying out its duties. |
|
20. |
The Committee shall prepare the report required by the rules of
the Commission to be included in the Companys proxy
statement for its annual meeting of stockholders. |
|
21. |
The Committee shall direct any special investigations deemed
necessary or appropriate by the Board or any of its committees. |
|
22. |
The Committee shall monitor compliance of the Companys
employees with its standards of business conduct and conflict of
interest policies and review reports and disclosures of insider
and affiliated party transactions. |
|
23. |
The Committee shall make regular reports to the Board with
respect to actions taken by the Committee. |
|
24. |
The Audit Committee may form and delegate authority to
subcommittees consisting of one or more members when
appropriate, including the authority to grant pre-approvals of
audit and permitted non-audit services, provided that decisions
of such subcommittee to grant pre-approvals shall be presented
to the full Committee at its next scheduled meeting. |
|
25. |
The Committee shall review and reassess the adequacy of this
Committees charter annually and recommend any proposed
changes to the Board for approval. |
|
26. |
The Committee shall annually review its own performance. |
A-4
APPENDIX B
AMENDED AND RESTATED
MEDICAL PROPERTIES TRUST, INC.
2004 EQUITY INCENTIVE PLAN
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
Page | |
ARTICLE 1. DEFINITIONS |
|
|
B-1 |
|
|
ARTICLE 2. COMMON STOCK SUBJECT TO PLAN |
|
|
B-4 |
|
2.1
|
|
Common Stock Subject to Plan |
|
|
B-4 |
|
2.2
|
|
Add-back of Grants |
|
|
B-4 |
|
|
ARTICLE 3. ELIGIBILITY; GRANTS; AWARD AGREEMENTS |
|
|
B-4 |
|
3.1
|
|
Eligibility |
|
|
B-4 |
|
3.2
|
|
Awards |
|
|
B-4 |
|
3.3
|
|
Provisions Applicable to Section 162(m) Participants |
|
|
B-5 |
|
3.4
|
|
Award Agreement |
|
|
B-5 |
|
|
ARTICLE 4. OPTIONS |
|
|
B-5 |
|
4.1
|
|
Award Agreement for Option Grant |
|
|
B-5 |
|
4.2
|
|
Option Price |
|
|
B-6 |
|
4.3
|
|
Qualification for Incentive Stock Options |
|
|
B-6 |
|
4.4
|
|
Change in Incentive Stock Option Grant |
|
|
B-6 |
|
4.5
|
|
Option Term |
|
|
B-6 |
|
4.6
|
|
Option Exercisability and Vesting |
|
|
B-6 |
|
4.7
|
|
Fair Market Value |
|
|
B-7 |
|
|
ARTICLE 5. EXERCISE OF OPTIONS |
|
|
B-7 |
|
5.1
|
|
Exercise |
|
|
B-7 |
|
5.2
|
|
Manner of Exercise |
|
|
B-7 |
|
5.3
|
|
Conditions to Issuance of Common Stock |
|
|
B-8 |
|
5.4
|
|
Rights as Stockholders |
|
|
B-8 |
|
5.5
|
|
Ownership and Transfer Restrictions |
|
|
B-8 |
|
5.6
|
|
Limitations on Exercise of Options |
|
|
B-8 |
|
|
ARTICLE 6. STOCK AWARDS |
|
|
B-9 |
|
6.1
|
|
Award Agreement |
|
|
B-9 |
|
6.2
|
|
Awards of Restricted Common Stock, Restricted Stock Units and
Deferred Stock Units |
|
|
B-9 |
|
6.3
|
|
Rights as Stockholders |
|
|
B-9 |
|
6.4
|
|
Restriction |
|
|
B-9 |
|
6.5
|
|
Lapse of Restrictions |
|
|
B-10 |
|
6.6
|
|
Repurchase of Restricted Common Stock |
|
|
B-10 |
|
6.7
|
|
Escrow |
|
|
B-10 |
|
6.8
|
|
Legend |
|
|
B-10 |
|
6.9
|
|
Conversion |
|
|
B-10 |
|
TABLE OF CONTENTS
(CONT.)
|
|
|
|
|
|
|
|
|
|
|
Page | |
|
ARTICLE 7. STOCK APPRECIATION RIGHTS |
|
|
B-10 |
|
7.1
|
|
Award Agreement for SARs |
|
|
B-10 |
|
7.2
|
|
General Requirements |
|
|
B-10 |
|
7.3
|
|
Base Amount |
|
|
B-10 |
|
7.4
|
|
Tandem SARs |
|
|
B-11 |
|
7.5
|
|
SAR Exercisability |
|
|
B-11 |
|
7.6
|
|
Value of SARs |
|
|
B-11 |
|
7.7
|
|
Form of Payment |
|
|
B-11 |
|
|
ARTICLE 8. PERFORMANCE UNITS |
|
|
B-11 |
|
8.1
|
|
Award Agreement for Performance Units |
|
|
B-11 |
|
8.2
|
|
General Requirements |
|
|
B-11 |
|
8.3
|
|
Performance Period and Performance Goals |
|
|
B-11 |
|
8.4
|
|
Payment With Respect to Performance Units |
|
|
B-12 |
|
|
ARTICLE 9. DEFERRALS |
|
|
B-12 |
|
|
ARTICLE 10. ADMINISTRATION |
|
|
B-12 |
|
10.1
|
|
Committee |
|
|
B-12 |
|
10.2
|
|
Duties and Powers of Committee |
|
|
B-12 |
|
10.3
|
|
Compensation; Professional Assistance; Good Faith Actions |
|
|
B-12 |
|
|
ARTICLE 11. MISCELLANEOUS PROVISIONS |
|
|
B-13 |
|
11.1
|
|
Transferability |
|
|
B-13 |
|
11.2
|
|
Amendment, Suspension or Termination of this Plan |
|
|
B-13 |
|
11.3
|
|
Changes in Common Stock or Assets of the Company, Acquisition or
Liquidation of the Company and Other Corporate Events |
|
|
B-13 |
|
11.4
|
|
Continued Employment |
|
|
B-15 |
|
11.5
|
|
Tax Withholding |
|
|
B-15 |
|
11.6
|
|
Forfeiture Provisions |
|
|
B-15 |
|
11.7
|
|
Limitations Applicable to Section 16 Persons and
Performance-Based Compensation |
|
|
B-15 |
|
11.8
|
|
Restrictions |
|
|
B-16 |
|
11.9
|
|
Restrictive Legend |
|
|
B-16 |
|
11.10
|
|
Effect of Plan Upon Option and Compensation Plans |
|
|
B-16 |
|
11.11
|
|
Compliance with Laws |
|
|
B-16 |
|
11.12
|
|
Titles |
|
|
B-17 |
|
11.13
|
|
Governing Law |
|
|
B-17 |
|
B-ii
AMENDED AND RESTATED
MEDICAL PROPERTIES TRUST, INC.
2004 EQUITY INCENTIVE PLAN
WHEREAS, the Company adopted, effective as of March 31,
2004, the Medical Properties Trust, Inc. 2004 Equity Incentive
Plan (the Plan), which allows for the grant of
equity-based awards in the form of stock options, restricted
common stock, restricted stock units, deferred stock units,
stock appreciation rights, and performance units and other
incentive compensation arrangements to employees, directors and
consultants of the Company and its subsidiaries in order to
attract and retain directors, executive officers and other key
employees and consultants;
WHEREAS, the Company amended and restated the Plan effective as
of October 18, 2004;
WHEREAS, Section 11.2 of the Plan provides that the Plan
may be amended at any time, in whole or in part, by action of
the Companys Board of Directors; and
WHEREAS, it is now desired to amend and restate the Plan in its
entirety to reflect such further amendments to the Plan as have
been approved by the Board of Directors.
NOW, THEREFORE, pursuant to the authority granted by the Board
of Directors, the Plan is hereby amended and restated, effective
as of October 12, 2005, as follows:
Medical Properties Trust, Inc., a Maryland corporation (the
Company), has established the Second Amended and
Restated Medical Properties Trust, Inc. 2004 Equity Incentive
Plan (the Plan), for the benefit of Employees,
Consultants and Directors of the Company and MPT Operating
Partnership, L.P.
The purposes of this Plan are (a) to recognize and
compensate selected Employees, Consultants and Directors who
contribute to the development and success of the Company and its
Affiliates and Subsidiaries, (b) to attract and retain,
Employees, Consultants and Directors, and (c) to provide
incentive compensation to Employees, Consultants and Directors
based upon the performance of the Company and its Affiliates and
Subsidiaries.
ARTICLE 1. DEFINITIONS
Wherever the following initially capitalized terms are used in
this Plan, they shall have the meanings specified below, unless
the context clearly indicates otherwise.
Affiliate shall mean any entity that directly or
indirectly through one or more intermediaries, controls, is
controlled by, or is under common control with the Company,
including without limitation, MPT Operating Partnership, L.P.
Award shall mean the grant or award of Options,
Restricted Common Stock, Restricted Stock Units, Deferred Stock
Units, SARs or Performance Units under this Plan.
Award Agreement shall mean the agreement granting or
awarding Options, Restricted Common Stock, Restricted Stock
Units, Deferred Stock Units, SARs or Performance Units.
Board shall mean the Board of Directors of the
Company, as comprised from time to time.
Cause shall mean (i) the conviction of the
Employee of, or the entry of a plea of guilty or nolo contendere
by the Employee to, a felony (exclusive of any felony relating
to negligent operation of a motor vehicle and not including a
conviction, plea of guilty or nolo contendere arising solely
under a statutory provision imposing criminal liability upon the
Employee on a per se basis due to the Company offices held by
the Employee, so long as any act or omission of the Employee
with respect to such matter was not taken or omitted in
contravention of any applicable policy or directive of the
Board), (ii) a willful breach of his duty of loyalty which
is materially detrimental to the Company, (iii) a willful
failure to perform or adhere to explicitly stated duties that
are consistent with the terms of his position with the Company,
or the Companys reasonable and customary guidelines of
employment or reasonable and customary corporate governance
guidelines or policies,
including without limitation any business code of ethics adopted
by the Board, or to follow the lawful directives of the Board
(provided such directives are consistent with the terms of the
Participants Employment Agreement), which, in any such
case, continues for thirty (30) days after written notice
from the Board to the Employee, or (iv) gross negligence or
willful misconduct in the performance of the Employees
duties. No act, or failure to act, on the Employees part
will be deemed gross negligence or willful
misconduct unless done, or omitted to be done, by the
Employee not in good faith and without a reasonable belief that
the Employees act, or failure to act, was in the best
interest of the Company. The Committee shall determine, in good
faith, if an Employee has been terminated for Cause.
Change of Control shall mean the occurrence of any
of the following events: (a) any person, entity or
affiliated group, excluding the Company or any employee benefit
plan of the Company, acquiring more than 50% of the then
outstanding shares of voting stock of the Company, (b) the
consummation of any merger or consolidation of the Company into
another company, such that the holders of the shares of the
voting stock of the Company immediately before such merger or
consolidation own less than 50% of the voting power of the
securities of the surviving company or the parent of the
surviving company, (c) the adoption of a plan for complete
liquidation of the Company or for the sale or disposition of all
or substantially all of the Companys assets, such that
after the transaction, the holders of the shares of the voting
stock of the Company immediately prior to the transaction own
less than 50% of the voting securities of the acquiror or the
parent of the acquiror, or (d) during any period of two
(2) consecutive years, individuals who at the beginning of
such period constituted the Board (including for this purpose
any new director whose election or nomination for election by
the Companys stockholders was approved by a vote of at
least a majority of the directors then still in office who were
directors at the beginning of such period) cease for any reason
to constitute at least a majority of the Board.
Code shall mean the Internal Revenue Code of 1986,
as amended.
Committee shall mean the Compensation Committee of
the Board.
Common Stock shall mean the common stock, par value
$0.001 per share, of the Company.
Company shall mean Medical Properties Trust, Inc., a
Maryland corporation, or any business organization which
succeeds to its business and elects to continue this Plan. For
purposes of this Plan, the term Company shall include, where
applicable, the employer of the Employee or Consultant,
including without limitation MPT Operating Partnership, L.P. or
such other Affiliate or Subsidiary that employs the Employee or
the Consultant.
Consultant shall mean a professional or technical
expert, consultant or independent contractor who provides
services to the Company or an Affiliate or Subsidiary, and who
may be selected to participate in the Plan.
Deferred Stock Unit shall mean a right to receive
Common Stock awarded under Article 6 of this Plan.
Director means any individual who is a member of the
Board.
Employee shall mean any employee (as defined in
accordance with the regulations and revenue rulings then
applicable under Section 3401(c) of the Code) of the
Company or an Affiliate or Subsidiary of the Company, whether
such employee was so employed at the time this Plan was
initially adopted or becomes so employed subsequent to the
adoption of this Plan.
Employment Agreement shall mean the employment,
consulting or similar contractual agreement entered into by the
Employee or the Consultant, as the case may be, and the Company
governing the terms of the Employees or Consultants
employment with the Company, if any.
Exchange Act shall mean the Securities Exchange Act
of 1934, as amended.
Fair Market Value of a share of Common Stock, as of
a given date, shall be determined pursuant to Section 4.7.
Good Reason shall only apply, and shall only have
the meaning, as contained in the Participants Employment
Agreement. Any provision herein that relates to a Termination of
Employment by the
B-2
Participant for Good Reason shall have no effect if there is no
Employment Agreement or the Employment Agreement does not
contain a provision permitting the Participant to terminate for
Good Reason.
Incentive Stock Option shall mean an option which
conforms to the applicable provisions of Section 422 of the
Code and which is designated as an Incentive Stock Option by the
Committee.
Independent Director shall mean a Director who is
not an Employee.
MPT OP means MPT Operating Partnership, L.P., of
which the Company is presently a limited partner and the sole
owner of the general partner.
Non-Qualified Stock Option shall mean an Option
which the Committee does not designate as an Incentive Stock
Option.
144A Offering means the private placement of Common
Stock of the Company.
Option shall mean an option to purchase shares of
Common Stock that is granted under Article 4 of this Plan.
An option granted under this Plan shall, as determined by the
Committee, be either a Non-Qualified Stock Option or an
Incentive Stock Option; provided, however, that Options granted
to Independent Directors and Consultants shall be Non-Qualified
Stock Options.
Participant shall mean an Employee, Consultant or
Director who has been determined as eligible to receive an Award
pursuant to Section 3.2.
Performance Units shall mean performance units
granted under Article 8 of this Plan.
Permanent Disability or Permanently
Disabled shall mean the inability of a Participant, due to
a physical or mental impairment, to perform the material
services of the Participants position with the Company for
a period of six (6) months, whether or not consecutive,
during any 365-day period. A determination of Permanent
Disability shall be made by a physician satisfactory to both the
Participant and the Committee, provided that if the Participant
and the Committee do not agree on a physician, each of them
shall select a physician and those two physicians together shall
select a third physician, whose determination as to Permanent
Disability shall be binding on all parties.
Plan shall mean the Second Amended and Restated
Medical Properties Trust, Inc. 2004 Equity Incentive Plan, as
embodied herein and as amended from time to time.
Plan Year shall mean the fiscal year of the Company.
Restricted Common Stock shall mean Common Stock
awarded under Article 6 of this Plan.
Restricted Stock Unit shall mean a right to receive
Common Stock awarded under Article 6 of this Plan.
Retirement or Retire shall, except as
otherwise defined in the Participants Employment
Agreement, mean a Participants Termination of Employment
with the Company on or after his 65th birthday.
Rule 16b-3 shall mean that certain
Rule 16b-3 under the Exchange Act, as such rule may be
amended from time to time.
SAR shall mean stock appreciation rights awarded
under Article 7 of this Plan.
Section 162(m) Participant shall mean any
Employee the Committee designates to receive an Award whose
compensation for the fiscal year in which the Employee is so
designated or a future fiscal year may be subject to the limit
on deductible compensation imposed by Section 162(m) of the
Code, as determined by the Committee in its sole discretion.
Stock Award shall mean an Award of Restricted Common
Stock, Restricted Stock Units or Deferred Stock Units under
Article 6 of this Plan.
Stock Award Account shall mean the bookkeeping
account reflecting Awards of Restricted Stock Units and Deferred
Stock Units under Article 6 of this Plan.
B-3
Subsidiary shall mean an entity in an unbroken chain
beginning with the Company if each of the entities other than
the last entity in the unbroken chain owns 50 percent or
more of the total combined voting power of all classes of equity
in one of the other entities in such chain.
Termination of Employment shall mean the date on
which the employee-employer, consulting, contractual or similar
relationship between a Participant and the Company is terminated
for any reason, with or without Cause, including, but not by way
of limitation, a termination of employment by resignation,
discharge, death, Permanent Disability or Retirement, but
excluding (i) termination of employment where there is a
simultaneous reemployment or continuing employment of a
Participant by the Company, and (ii) at the discretion of
the Committee, termination of employment which results in a
temporary severance of the employee-employer relationship. The
Committee, in its absolute discretion, shall determine the
effect of all matters and questions relating to a Termination of
Employment (subject to the provisions of any Employment
Agreement between a Participant and the Company), including, but
not limited to all questions of whether particular leaves of
absence constitute a Termination of Employment; provided,
however, that, unless otherwise determined by the Committee in
its discretion, a leave of absence, change in status from an
employee to an independent contractor or other change the
employee-employer, consulting, contractual or similar
relationship shall constitute a Termination of Employment if,
and to the extent that, such leave of absence, change in status
or other change interrupts employment for the purposes of
Section 422(a)(2) of the Code and the then applicable
regulations and revenue rulings under said Section.
ARTICLE 2. COMMON STOCK
SUBJECT TO PLAN
|
|
2.1 |
COMMON STOCK SUBJECT TO PLAN. |
2.1.1 The Common Stock subject to an Award shall be shares
of the Companys authorized but unissued, reacquired, or
treasury Common Stock. Subject to adjustment as described in
Section 11.3.1, the aggregate number of shares of Common
Stock that may be issued under the Plan as Restricted Common
Stock, Restricted Stock Units, Deferred Stock Units or pursuant
to the exercise of Options is 4,691,180.
2.1.2 The maximum number of shares of Common Stock which
may be awarded to any individual in any calendar year shall not
exceed 300,000.
2.2 ADD-BACK OF GRANTS. If any
Option or SAR expires or is canceled without having been fully
exercised, is exercised in whole or in part for cash as
permitted by this Plan, or is exercised prior to becoming vested
as permitted under Section 4.6.3 and is forfeited prior to
becoming vested, the number of shares of Common Stock subject to
such Option or SAR but as to which such Option, SAR or other
right was not exercised or vested prior to its expiration,
cancellation or exercise may again be optioned, granted or
awarded hereunder. Shares of Common Stock which are delivered by
the Participant or withheld by the Company upon the exercise of
any Option or other award under this Plan, in payment of the
exercise price thereof, may again be optioned, granted or
awarded hereunder. If any shares of Common Stock awarded as
Restricted Common Stock, Restricted Stock Units or other equity
award hereunder or as payment for Performance Units are
forfeited by the Participant, such shares may again be optioned,
granted or awarded hereunder. Notwithstanding the provisions of
this Section 2.2, no shares of Common Stock may again be
optioned, granted or awarded pursuant to an Incentive Stock
Option if such action would cause such Option to fail to qualify
as an Incentive Stock Option under Section 422 of the Code.
ARTICLE 3. ELIGIBILITY;
GRANTS; AWARD AGREEMENTS
3.1 ELIGIBILITY. Any Employee,
Consultant or Director selected to participate pursuant to
Section 3.2 shall be eligible to participate in the Plan.
3.2 AWARDS. The Committee shall
determine which Employees, Consultants and Directors, shall
receive Awards, whether the Employee, Consultant or Director
will receive Options, Restricted Common Stock, Restricted Stock
Units, Deferred Stock Units, SARs or Performance Units, whether
an Option grant shall be of Incentive Stock Options or
Non-Qualified Stock Options, and the number of shares of Common
Stock
B-4
subject to such Award. Notwithstanding the foregoing, the terms
and conditions of an Award intended to qualify as
performance-based compensation as described in
Section 162(m)(4)(C) of the Code shall include, but not be
limited to, such terms and conditions as may be necessary to
meet the applicable provisions of Section 162(m) of the
Code.
|
|
3.3 |
PROVISIONS APPLICABLE TO SECTION 162(m) PARTICIPANTS. |
3.3.1 Notwithstanding anything in the Plan to the contrary,
the Committee may grant Options, Restricted Common Stock,
Restricted Stock Units, SARs or Performance Units to a
Section 162(m) Participant that vest upon the attainment of
performance targets for the Company which are related to one or
more of the following performance goals: (i) pre-tax
income, (ii) operating income, (iii) cash flow,
(iv) earnings per share, (v) return on equity,
(vi) return on invested capital or assets, (vii) cost
reductions or savings, or (vii) such other identifiable and
measurable performance objectives, as determined by the
Committee.
3.3.2 To the extent necessary to comply with the
performance-based compensation requirements of
Section 162(m)(4)(C) of the Code, no later than ninety
(90) days following the commencement of any fiscal year in
question or any other designated fiscal period (or such other
time as may be required or permitted by Section 162(m) of
the Code), the Committee shall, in writing, (i) designate
one or more Section 162(m) Participants, (ii) select
the performance goal or goals applicable to the fiscal year or
other designated fiscal period, (iii) establish the various
targets and bonus amounts which may be earned for such fiscal
year or other designated fiscal period and (iv) specify the
relationship between performance goals and targets and the
amounts to be earned by each Section 162(m) Participant for
such fiscal year or other designated fiscal period. Following
the completion of each fiscal year or other designated fiscal
period, the Committee shall certify in writing whether the
applicable performance targets have been achieved for such
fiscal year or other designated fiscal period. In determining
the amount earned by a Section 162(m) Participant, the
Committee shall have the right to reduce (but not to increase)
the amount payable at a given level of performance to take into
account additional factors that the Committee may deem relevant
to the assessment of individual or corporate performance for the
fiscal year or other designated fiscal period.
3.4 AWARD AGREEMENT. Upon the
selection of an Employee, Consultant or Director to become a
Participant and receive an Award, the Committee shall cause a
written Award Agreement to be issued to such individual
encompassing the terms and conditions of such Award, as
determined by the Committee in its sole discretion; provided,
however, that if applicable, the terms of such Award Agreement
shall comply with the terms of such Participants
Employment Agreement, if any. Such Award Agreement shall provide
for the exercise price for Options and SARs; the purchase price
for Restricted Common Stock, Restricted Stock Units and Deferred
Stock Units; the performance criteria for Performance Units; and
the exercisability and vesting schedule, payment terms and such
other terms and conditions of such Award, as determined by the
Committee in its sole discretion. Each Award Agreement shall be
executed by the Participant and an officer or a Director (other
than the Participant) of the Company authorized to sign such
Award Agreement and shall contain such terms and conditions that
are consistent with the Plan, including but not limited to the
exercisability and vesting schedule, if any, as the Committee in
its sole discretion shall determine. All Awards shall be made
conditional upon the Participants acknowledgment, in
writing in the Award Agreement or otherwise by acceptance of the
Award, that all decisions and determinations of the Committee
shall be final and binding on the Participant, his beneficiaries
and any other person having or claiming an interest under such
Award.
ARTICLE 4. OPTIONS
4.1 AWARD AGREEMENT FOR OPTION
GRANT. Option grants shall be evidenced by an Award Agreement,
pursuant to Section 3.4. All Award Agreements evidencing
Options intended to qualify as performance-based compensation as
described in Section 162(m)(4)(C) of the Code shall contain
such terms and conditions as may be necessary to meet the
applicable provisions of Section 162(m) of the Code. All
Award Agreements evidencing Incentive Stock Options shall
contain such terms and conditions as may be necessary to meet
the applicable provisions of Section 422 of the Code.
B-5
4.2 OPTION PRICE. The price per
share of the Common Stock subject to each Option shall be set by
the Committee; provided, however, that (i) such price shall
not be less than the par value of a share of Common Stock and
shall not be less than 100% of the Fair Market Value of a share
of Common Stock on the date the Option is granted, (ii) in
the case of Incentive Stock Options granted to an individual
then owning (within the meaning of Section 424(d) of the
Code) more than 10% of the total combined voting power of all
classes of stock of the Company or any Subsidiary or parent
corporation thereof (within the meaning of Section 422 of
the Code), such price shall not be less than 110% of the Fair
Market Value of a share of Common Stock on the date the Option
is granted.
4.3 QUALIFICATION FOR INCENTIVE
STOCK OPTIONS. The Committee may grant an Incentive Stock Option
to an individual if such person is an Employee of the Company or
is an Employee of an Affiliate or Subsidiary as permitted under
Section 422(a)(2) of the Code.
4.4 CHANGE IN INCENTIVE STOCK
OPTION GRANT. Any Incentive Stock Option granted under this Plan
may be modified by the Committee to disqualify such Option from
treatment as an Incentive Stock Option under Section 422 of
the Code. To the extent that the aggregate Fair Market Value of
shares of Common Stock with respect to which Incentive Stock
Options (within the meaning of Section 422 of the Code, but
without regard to Section 422(d) of the Code) are
exercisable for the first time by a Participant during any
calendar year (under the Plan and all other Incentive Stock
Option plans of the Company) exceeds $100,000, such Options
shall be treated as Non-Qualified Stock Options to the extent
required or permitted by Section 422 of the Code. The rule
set forth in the preceding sentence shall be applied by taking
Options into account in the order in which they were granted.
For purposes of this Section 4.4, the Fair Market Value of
shares of Common Stock shall be determined as of the time the
Option with respect to such shares of Common Stock is granted,
pursuant to Section 4.7.
4.5 OPTION TERM. The term of an
Option shall be set by the Committee in its discretion;
provided, however, in the case of Incentive Stock Options, the
term shall not be more than ten (10) years from the date
the Incentive Stock Option is granted, or five (5) years
from such date if the Incentive Stock Option is granted to an
Employee then owning (within the meaning of Section 424(d)
of the Code) more than 10% of the total combined voting power of
all classes of stock of the Company or any Subsidiary or parent
corporation thereof (within the meaning of Section 422 of
the Code). Such Incentive Stock Options shall be subject to
Section 5.6, except as limited by the requirements of
Section 422 of the Code and regulations and rulings
thereunder applicable to Incentive Stock Options.
|
|
4.6 |
OPTION EXERCISABILITY AND VESTING. |
4.6.1 The period during which Options in whole or in part
become exercisable and vest in the Participant shall be set by
the Committee and shall be as provided for in the Award
Agreement. At any time after the grant of an Option, the
Committee may, in its sole and absolute discretion and subject
to whatever terms and conditions it selects, accelerate the
period during which an Option becomes exercisable and vests.
4.6.2 In each Award Agreement, the Committee shall indicate
whether the portion of the Options, if any, that remains
non-exercisable and non-vested upon the Participants
Termination of Employment with the Company is forfeited. In so
specifying, the Committee may differentiate between the reason
for the Participants Termination of Employment.
4.6.3 At any time on or after the grant of an Option, the
Committee may provide in an Award Agreement that the Participant
may elect to exercise part or all of an Option before it
otherwise has become exercisable. Any shares of Common Stock so
purchased shall be restricted Common Stock and shall be subject
to a repurchase right in favor of the Company during a specified
restriction period, with the repurchase price equal to the
lesser of (i) the price per share paid by the Participant
for the Common Stock, or (ii) the Fair Market Value of such
Common Stock at the time of repurchase, or such other
restrictions as the Committee deems appropriate. The Participant
shall have, unless otherwise provided by the Committee in the
Award Agreement, all the rights of an owner of Common Stock,
subject to the restrictions and provisions of his Award
Agreement, including the right to vote such Common Stock and to
receive all dividends and other distributions paid or made with
respect to Common Stock.
B-6
4.6.4 Any Options which are not exercisable and vested upon
the occurrence of a Change of Control, including shares of
restricted Common Stock received upon the exercise of an Option
as described in Section 4.6.3 above, shall become 100%
exercisable, if not previously exercised, and 100% vested,
unless the Award Agreement or the Participants Employment
Agreement provides otherwise.
4.7 FAIR MARKET VALUE. The Fair
Market Value of a share of Common Stock as of a given date shall
be (i) the closing price of a share of Common Stock on the
principal exchange on which shares of Common Stock are then
trading, if any (or as reported on any composite index which
includes such principal exchange), on the trading day previous
to such date, or if shares of Common Stock were not traded on
the trading day previous to such date, then on the next
preceding date on which a trade occurred, or (ii) if shares
of Common Stock are not traded on an exchange but are quoted on
NASDAQ or a successor quotation system, either the
(a) closing sale price, or (b) the mean between the
closing representative bid and asked prices for the Common Stock
on the trading day previous to such date as reported by NASDAQ
or such successor quotation systems, as may be appropriate, or
(iii) if shares of Common Stock are not publicly traded on
an exchange and not quoted on NASDAQ or a successor quotation
system, the Fair Market Value of a share of Common Stock as
established by the Company acting in good faith and after
consultation with independent advisors. The Fair Market Value as
so determined by the Company in good faith and in the absence of
fraud shall be binding and conclusive upon all parties hereto,
and in any event the Participant agrees to accept and shall not
challenge any such determination of Fair Market Value made by
the Company. If the Company subdivides (by split, dividend or
otherwise) its shares of Common Stock into a greater number, or
combines (by reverse split or otherwise) its shares of Common
Stock into a lesser number after the Company shall have
determined the Fair Market Value for the shares of Common Stock
subject to an Award (without taking into consideration such
subdivision or combination) and prior to the consummation of the
purchase, the Fair Market Value shall be appropriately adjusted
to reflect such subdivision or combination, and the
Companys good faith determination as to any such
adjustment shall be binding and conclusive on all parties hereto.
ARTICLE 5. EXERCISE OF OPTIONS
5.1 EXERCISE. At any time and from
time to time prior to the time when any exercisable Option or
portion thereof becomes unexercisable under the Plan or the
Award Agreement, such Option or portion thereof may be exercised
in whole or in part; provided, however, that the Company shall
not be required to issue fractional shares of Common Stock and
the Committee may, by the terms of the Option, require any
partial exercise to be with respect to a minimum number of
shares of Common Stock.
5.2 MANNER OF EXERCISE. An
exercisable Option, or any exercisable portion thereof, may be
exercised solely by delivery to the Company of all of the
following prior to the time when such Option or such portion
becomes unexercisable under the Plan or the Award Agreement:
5.2.1 A written notice signed by the Participant or other
person then entitled to exercise such Option or portion thereof,
stating that such Option or portion is being exercised, provided
such notice complies with all applicable rules established by
the Committee from time to time.
5.2.2 Such representations and documents as the Committee,
in its absolute discretion, deems necessary or advisable to
effect compliance with all applicable provisions of the
Securities Act of 1933, as amended, and any other federal or
state securities laws or regulations. The Committee may, in its
absolute discretion, also take whatever additional actions it
deems appropriate to effect such compliance including, without
limitation, causing legends to be placed on certificates for
shares of Common Stock and issuing stop-transfer notices to
agents and registrars.
5.2.3 In the event that the Option shall be exercised
pursuant to Section 11.1 by any person or persons other
than the Participant, appropriate proof of the right of such
person or persons to exercise the Option or portion thereof.
B-7
5.2.4 Full payment (in cash or by a certified check) for
the shares of Common Stock with respect to which the Option or
portion thereof is exercised, including the amount of any
withholding tax due, unless with the prior written consent of
the Committee:
5.2.4.1 payment, in whole or in part, is made through the
delivery of shares of Common Stock owned by the Participant,
duly endorsed for transfer to the Company with a Fair Market
Value on the date of delivery equal to the aggregate exercise
price of the Option or exercised portion thereof, provided, that
shares of Common Stock used to exercise the Option have been
held by the Participant for the requisite period of time to
avoid adverse accounting consequences to the Company with
respect to the Option;
5.2.4.2 payment, in whole or in part, is made through the
surrender of shares of Common Stock then issuable upon exercise
of the Option having a Fair Market Value on the date of Option
exercise equal to the aggregate exercise price of the Option or
exercised portion thereof;
5.2.4.3 after a public offering of the Common Stock,
payment through a broker at the time required in accordance with
procedures permitted by Regulation T of the Federal Reserve
Board; or
5.2.4.4 payment is made through any combination of the
consideration provided for in this Section 5.2.4 or such
other method approved by the Committee consistent with
applicable law.
5.3 CONDITIONS TO ISSUANCE OF
COMMON STOCK. The Company shall not be required to issue or
deliver any certificate or other indicia evidencing ownership of
shares of Common Stock purchased upon the exercise of any Option
or portion thereof prior to fulfillment of all of the following
conditions:
5.3.1 The obtaining of any approval or other clearance from
any state or federal governmental agency which the Committee
shall, in its sole discretion, determine to be necessary or
advisable.
5.3.2 The lapse of such reasonable period of time following
the exercise of the Option as the Committee may establish from
time to time for reasons of administrative convenience.
5.3.3 The receipt by the Company of full payment for such
Common Stock, including payment of any applicable withholding
tax.
5.3.4 The Participant agreeing to the terms and conditions
of the Plan and the Award Agreement.
5.4 RIGHTS AS STOCKHOLDERS. The
holders of Options shall not be, nor have any of the rights or
privileges of, stockholders of the Company in respect of any
shares of Common Stock purchasable upon the exercise of any part
of an Option unless and until certificates or other indicia
representing such shares of Common Stock have been issued by the
Company to such holders.
5.5 OWNERSHIP AND TRANSFER
RESTRICTIONS. The Committee, in its absolute discretion, may
impose at the time of grant such restrictions on the ownership
and transferability of the shares of Common Stock purchasable
upon the exercise of an Option as it deems appropriate. Any such
restriction shall be set forth in the Award Agreement and may be
referred to on the certificates or other indicia evidencing such
shares of Common Stock.
5.6 LIMITATIONS ON EXERCISE OF
OPTIONS.
5.6.1 Vested Incentive Stock Options may not be exercised
after the earlier of (i) their expiration date,
(ii) twelve (12) months from the date of the
Participants Termination of Employment by reason of his
death, (iii) twelve (12) months from the date of the
Participants Termination of Employment by reason of his
Permanent Disability, or (iv) the expiration of three
(3) months from the date of the Participants
Termination of Employment for any reason other than such
Participants death or Permanent Disability, unless the
Participant dies within said three (3) month period. Leaves
of absence for less than ninety (90) days shall not cause a
Termination of Employment for purposes of Incentive Stock
Options.
5.6.2 Non-Qualified Stock Options may be exercised up until
their expiration date, unless the Committee provides otherwise
in the Award Agreement.
B-8
ARTICLE 6. STOCK AWARDS
6.1 AWARD AGREEMENT. Awards of
Restricted Common Stock, Restricted Stock Units and Deferred
Stock Units shall be evidenced by an Award Agreement, pursuant
to Section 3.4. All Award Agreements evidencing Restricted
Common Stock, Restricted Stock Units and Deferred Stock Units
intended to qualify as performance-based compensation as
described in Section 162(m)(4)(C) of the Code shall contain
such terms and conditions as may be necessary to meet the
applicable provisions of Section 162(m) of the Code.
6.2 AWARDS OF RESTRICTED COMMON
STOCK, RESTRICTED STOCK UNITS AND DEFERRED STOCK UNITS.
6.2.1 The Committee may from time to time, in its absolute
discretion, consistent with this Plan:
6.2.1.1 determine which Employees, Consultants and
Directors shall receive Stock Awards;
6.2.1.2 determine the aggregate number of shares of Common
Stock to be awarded as Stock Awards to Employees, Consultants
and Directors;
6.2.1.3 determine the terms and conditions applicable to
such Stock Awards; and
6.2.1.4 determine when the restrictions, if any, lapse.
6.2.2 The Committee may establish the purchase price, if
any, and form of payment for a Stock Award. If the Committee
establishes a purchase price, the purchase price shall be no
less than the par value of the Common Stock to be purchased,
unless otherwise permitted by applicable state law.
6.2.3 Upon the selection of an Employee, Consultant or
Director to be awarded Restricted Common Stock, the Committee
shall instruct the Secretary of the Company to issue such
Restricted Common Stock and may impose such conditions on the
issuance of such Restricted Common Stock as it deems
appropriate, subject to the provisions of Article 9.
6.2.4 Upon the selection of an Employee, Consultant or
Director to be awarded Restricted Stock Units or Deferred Stock
Units, the Committee shall instruct the Secretary of the Company
to establish a Stock Award Account on behalf of each such
Participant. The Committee may impose such conditions on the
issuance of such Restricted Stock Units or Deferred Stock Units
as it deems appropriate.
6.2.5 Awards of Restricted Common Stock and Restricted
Stock Units shall vest pursuant to the Award Agreement.
6.2.6 A Participant shall be 100 percent vested in the
number of Deferred Stock Units held in his or her Stock Award
Account at all times. The term for which the Deferred Stock
Units shall be deferred shall be provided for in the Award
Agreement.
6.3 RIGHTS AS STOCKHOLDERS.
6.3.1 Upon delivery of the shares of Restricted Common
Stock to the Participant or the escrow holder pursuant to
Section 6.7, the Participant shall have, unless otherwise
provided by the Committee in the Award Agreement, all the rights
of an owner of Common Stock, subject to the restrictions and
provisions of his Award Agreement; provided, however, that in
the discretion of the Committee, any extraordinary distributions
with respect to the Common Stock shall be subject to the
restrictions set forth in Section 6.4.
6.3.2 Nothing in this Plan shall be construed as giving a
Participant who receives an Award of Restricted Stock Units or
Deferred Stock Units any of the rights of an owner of Common
Stock unless and until shares of Common Stock are issued and
transferred to the Participant in accordance with the terms of
the Plan and the Award Agreement. Notwithstanding the foregoing,
in the event that any dividend is paid by the Company with
respect to the Common Stock (whether in the form of cash, Common
Stock or other property), then the Committee shall, in the
manner it deems equitable or appropriate, adjust the number of
Restricted Stock Units or Deferred Stock Units allocated to each
Participants Stock Award Account to reflect such dividend.
6.4 RESTRICTION. All shares of
Restricted Common Stock issued under this Plan (including any
Common Stock received as a result of stock dividends, stock
splits or any other form of recapitalization, if
B-9
any) shall at the time of the Award, in the terms of each
individual Award Agreement, be subject to such restrictions as
the Committee shall, in its sole discretion, determine, which
restrictions may include, without limitation, restrictions
concerning voting rights, transferability, vesting, Company
performance and individual performance; provided, however, that
by action taken subsequent to the time shares of Restricted
Common Stock are issued, the Committee may, on such terms and
conditions as it may determine to be appropriate, remove any or
all of the restrictions imposed by the terms of the Award
Agreement. Restricted Common Stock may not be sold or encumbered
until all restrictions are terminated or expire.
6.5 LAPSE OF RESTRICTIONS. The
restrictions on Awards of Restricted Common Stock and Restricted
Stock Units shall lapse in accordance with the terms of the
Award Agreement. In the Award Agreement, the Committee shall
indicate whether shares of Restricted Common Stock or Restricted
Stock Units then subject to restrictions are forfeited or if the
restrictions shall lapse upon the Participants Termination
of Employment. In so specifying, the Committee may differentiate
between the reason for the Participants Termination of
Employment.
6.6 REPURCHASE OF RESTRICTED COMMON
STOCK. The Committee may provide in the terms of the Award
Agreement awarding Restricted Common Stock that the Company
shall have call rights, a right of first offer or a right of
refusal regarding shares of Restricted Common Stock then subject
to restrictions.
6.7 ESCROW. The Company may appoint
an escrow holder to retain physical custody of each certificate
or control of each other indicia representing shares of
Restricted Common Stock until all of the restrictions imposed
under the Award Agreement with respect to the shares of Common
Stock evidenced by such certificate expire or shall have been
removed.
6.8 LEGEND. In order to enforce the
restrictions imposed upon shares of Restricted Common Stock
hereunder, the Committee shall cause a legend or restrictions to
be placed on certificates of Restricted Common Stock that are
still subject to restrictions under Award Agreements, which
legend or restrictions shall make appropriate reference to the
conditions imposed thereby.
6.9 CONVERSION. Upon vesting in the
case of Restricted Stock Units, and upon the lapse of the
deferral period in the case of Deferred Stock Units, such
Restricted Stock Units or Deferred Stock Units shall be
converted into an equivalent number of shares of Common Stock
that will be distributed to the Participant, or in the case of
the Participants death, to the Participants legal
representative. Such distribution shall be evidenced by a stock
certificate, appropriate entry on the books of the Company or of
a duly authorized transfer agent of the Company, or other
appropriate means as determined by the Company. In the event
ownership or issuance of the Common Stock is not feasible due to
applicable exchange controls, securities regulations, tax laws
or other provisions of applicable law, as determined by the
Company in its sole discretion, the Participant, or in the case
of the Participants death, the Participants legal
representative, shall receive cash proceeds in an amount equal
to the value of the shares of Common Stock otherwise
distributable to the Participant, net of tax withholding as
provided in Section 11.5.
ARTICLE 7. STOCK APPRECIATION
RIGHTS
7.1 AWARD AGREEMENT FOR SARS.
Awards of SARs shall be evidenced by an Award Agreement,
pursuant to Section 3.4. All Award Agreements evidencing
SARs intended to qualify as performance-based compensation as
described in Section 162(m)(4)(C) of the Code shall contain
such terms and conditions as may be necessary to meet the
applicable provisions of Section 162(m) of the Code.
7.2 GENERAL REQUIREMENTS. The
Committee may grant SARs separately or in tandem with any Option
(for all or a portion of the applicable Option). The Committee
shall determine which Employees, Consultants and Directors shall
receive Awards of SARs and the amount of such Awards.
7.3 BASE AMOUNT. The Committee
shall establish the base amount of the SAR at the time the SAR
is granted. Unless the Committee determines otherwise, the base
amount of each SAR shall be equal to the price per share of the
related Option or, if there is no related Option, the Fair
Market Value of a share of Common Stock as of the date of grant
of the SAR.
B-10
7.4 TANDEM SARS. Tandem SARs may be
granted either at the time the Option is granted or at any time
thereafter while the Option remains outstanding; provided,
however, that, in the case of an Incentive Stock Option, SARs
may be granted only at the time of grant of the Incentive Stock
Option. In the case of tandem SARs, the number of SARs granted
to an Employee, Consultant or Director that shall be exercisable
during a specified period shall not exceed the number of shares
of Common Stock that the Employee, Consultant or Director may
purchase upon the exercise of the related Option during such
period. Upon the exercise of an Option, the SARs relating to the
Common Stock covered by such Option shall terminate. Upon the
exercise of the SARs, the related Option shall terminate to the
extent of an equal number of shares of Common Stock.
7.5 SAR EXERCISABILITY.
7.5.1 The period during which SARs in whole or in part
become exercisable shall be set by the Committee and shall be as
provided for in the Award Agreement. At any time after the grant
of an SAR, the Committee may, in its sole and absolute
discretion and subject to whatever terms and conditions its
selects, accelerate the period during which the SAR becomes
exercisable.
7.5.2 In each Award Agreement, the Committee shall indicate
whether the portion of the SAR, if any, that remains
non-exercisable upon the Participants Termination of
Employment with the Company is forfeited. In so specifying, the
Committee may differentiate between the reason for the
Participants Termination of Employment.
7.6 VALUE OF SARS. When a
Participant exercises an SAR, the Participant shall receive in
settlement of such SAR an amount equal to the value of the stock
appreciation for the number of SARs exercised payable in cash,
Common Stock or a combination thereof. The stock appreciation
for an SAR is the amount by which the Fair Market Value of the
underlying Common Stock on the date of exercise of the SAR
exceeds the base amount of the SAR.
7.7 FORM OF PAYMENT. The Committee
shall determine whether the appreciation in an SAR shall be paid
in the form of cash, Common Stock or a combination of the two,
in such proportion as the Committee deems appropriate. For
purposes of calculating the number of shares of Common Stock to
be received, shares of Common Stock shall be valued at their
Fair Market Value on the date of exercise of the SAR. If shares
of Common Stock are received upon exercise of a SAR, cash shall
be delivered in lieu of any fractional shares of Common Stock.
ARTICLE 8. PERFORMANCE UNITS
8.1 AWARD AGREEMENT FOR PERFORMANCE
UNITS. Awards of Performance Units shall be evidenced by an
Award Agreement, pursuant to Section 3.4. All Award
Agreements evidencing Performance Units intended to qualify as
performance-based compensation as described in
Section 162(m)(4)(C) of the Code shall contain such terms
and conditions as may be necessary to meet the applicable
provisions of Section 162(m) of the Code.
8.2 GENERAL REQUIREMENTS. Each
Performance Unit shall represent the right of the Participant to
receive an amount based on the value of the Performance Unit, if
performance goals established by the Committee are met. A
Performance Unit shall be based on the Fair Market Value of a
share of Common Stock or such other measurement base as the
Committee deems appropriate. The Committee shall determine and
set forth in the Award Agreement the number of Performance Units
to be granted and the requirements applicable to such
Performance Units. The Committee shall determine which
Employees, Consultants and Directors shall receive Awards of a
Performance Unit and the amount of such Awards.
8.3 PERFORMANCE PERIOD AND
PERFORMANCE GOALS. When Performance Units are granted, the
Committee shall establish the performance period during which
performance shall be measured (the Performance
Period), performance goals applicable to the Performance
Units (Performance Goals) and such other conditions
of the Award as the Committee deems appropriate. Performance
Goals may relate to the financial performance of the Company or
its Subsidiaries, the performance of Common Stock, individual
performance or such other criteria as the Committee deems
appropriate.
B-11
8.4 PAYMENT WITH RESPECT TO
PERFORMANCE UNITS. At the end of each Performance Period, the
Committee shall determine to what extent the Performance Goals
and other conditions of the Performance Units are met, the value
of the Performance Units (if applicable), and the amount, if
any, to be paid with respect to the Performance Units. Payments
with respect to Performance Units shall be made in cash, in
Common Stock or in a combination of the two, as determined by
the Committee.
ARTICLE 9. DEFERRALS
The Committee may permit a Participant to defer receipt of the
payment of cash or the delivery of Common Stock that would
otherwise be due to such Participant in connection with any
Option or SAR, the lapse or waiver of restrictions applicable to
Restricted Common Stock or Restricted Stock Units, the lapse of
the deferral period applicable to Deferred Stock Units or the
satisfaction of any requirements or objectives with respect to
Performance Units. If any such deferral election is permitted,
the Committee shall, in its sole discretion, establish rules and
procedures for such deferrals, which may include provisions for
the payment or crediting of interest or dividend equivalents,
including converting such credits into deferred Common Stock
equivalents and restricting deferrals to comply with hardship
distribution rules affecting 401(k) plans. The Company may, but
is not obligated to, contribute the shares of Common Stock that
would otherwise be issuable pursuant to an Award to a rabbi
trust. Shares of Common Stock issued to a rabbi trust pursuant
to this Article 9 may ultimately be issued to the
Participant in accordance with the terms of the deferred
compensation plan or the Award Agreement.
ARTICLE 10. ADMINISTRATION
10.1 COMMITTEE. The Plan shall be
administered by the Compensation Committee of the Board. The
Board may remove members, add members, and fill vacancies on the
Committee from time to time, all in accordance with the
Companys Articles of Incorporation, by-laws, and with
applicable law. The majority vote of the Committee, or for acts
taken in writing without a meeting by the unanimous written
consent of the members of the Committee, shall be valid acts of
the Committee. Appointment of Committee members shall be
effective upon acceptance of appointment. Committee members may
resign at any time by delivering written notice to the Board.
10.2 DUTIES AND POWERS OF
COMMITTEE. It shall be the duty of the Committee to conduct the
general administration of this Plan in accordance with its
provisions. The Committee shall have the power to interpret this
Plan and the agreements pursuant to which Options, Restricted
Common Stock, Restricted Stock Units, Deferred Stock Units, SARs
and Performance Units are granted or awarded, and to adopt such
rules for the administration, interpretation, and application of
this Plan as are consistent therewith and to interpret, amend or
revoke any such rules. Any such Award under this Plan need not
be the same with respect to each Participant. Any such
interpretations and rules with respect to Incentive Stock
Options shall be consistent with the provisions of
Section 422 of the Code.
10.3 COMPENSATION; PROFESSIONAL
ASSISTANCE; GOOD FAITH ACTIONS. Unless otherwise determined by
the Board, members of the Committee shall receive no
compensation for their services pursuant to this Plan. All
expenses and liabilities which members of the Committee incur in
connection with the administration of this Plan shall be borne
by the Company. The Committee may, with the approval of the
Board, employ attorneys, consultants, accountants, appraisers,
brokers, or other persons. The Committee, the Company and the
Companys officers and Directors shall be entitled to rely
upon the advice, opinions or valuations of any such persons. All
actions taken and all interpretations and determinations made by
the Committee or the Board in good faith shall be final and
binding upon all Participants, the Company and all other
interested persons. No members of the Committee or Board shall
be personally liable for any action, determination or
interpretation made in good faith with respect to this Plan or
any Awards made hereunder, and all members of the Committee and
the Board shall be fully protected by the Company in respect of
any such action, determination or interpretation.
B-12
ARTICLE 11. MISCELLANEOUS
PROVISIONS
11.1 TRANSFERABILITY.
11.1.1 No Option, Restricted Common
Stock, Restricted Stock Unit, Deferred Stock Unit, SAR,
Performance Unit, or any right therein or part thereof shall be
liable for the debts, contracts or engagements of the
Participant or his successors in interest or shall be subject to
disposition by transfer, alienation, anticipation, pledge,
encumbrance, assignment or any other means, whether such
disposition be voluntary or involuntary or by operation of law
by judgment, levy, attachment, garnishment or any other legal or
equitable proceedings (including bankruptcy), and any attempted
disposition thereof shall be null and void and of no effect;
provided, however, that nothing in this Section 11.1.1
shall prevent transfers by will or by the applicable laws of
descent and distribution or as permitted in Section 11.1.2
below. The Committee shall not be required to accelerate the
exercisability of an Award or otherwise take any action pursuant
to a divorce or similar proceeding in the event
Participants spouse is determined to have acquired a
community property interest in all or any portion of an Award.
Except as provided below, during the lifetime of the
Participant, only he may exercise an Award (or any portion
thereof) granted to him under the Plan. After the death of the
Participant, any exercisable portion of an Award, prior to the
time when such portion becomes unexercisable under the Plan or
the applicable Award Agreement or other agreement, may be
exercised by his personal representative or by any person
empowered to do so under the deceased Participants will or
under the then applicable laws of descent and distribution.
11.1.2 Notwithstanding the foregoing, the Committee may
provide in an Award Agreement, or amend an otherwise outstanding
Award Agreement to provide, that a Participant may transfer
Non-Qualified Stock Options to family members, or one or more
trusts or other entities for the benefit of or owned by family
members, consistent with applicable securities laws, according
to such terms as the Committee may determine; provided that the
Participant receives no consideration for the transfer of a
Non-Qualified Stock Option and the transferred Non-Qualified
Stock Option shall continue to be subject to the same terms and
conditions as were applicable to the Non-Qualified Stock Option
immediately before the transfer and shall be exercisable by the
transferee according to the same terms as applied to the
Participant.
11.2 AMENDMENT, SUSPENSION OR
TERMINATION OF THIS PLAN.
11.2.1 Except as otherwise provided in this
Section 11.2, this Plan may be wholly or partially amended
or otherwise modified, suspended or terminated at any time or
from time to time by the Board; provided, however, no action of
the Board or the Committee may be taken that would otherwise
require stockholder approval as a matter of applicable law,
regulation or rule, without the consent of the stockholders. The
Board and the Committee cannot reprice, replace or regrant
through cancellation or by lowering the price per share of a
previously granted Option unless the stockholders of the Company
provide prior approval. No amendment, suspension or termination
of this Plan shall, without the consent of the Participant,
impair any rights or obligations under any Award theretofore
made to the Participant, unless such right has been reserved in
the Plan or the Award Agreement. No Award may be made during any
period of suspension or after termination of this Plan. In no
event may any Award be made under this Plan after March 31,
2014.
11.2.2 Notwithstanding the foregoing, the Board or the
Committee may take any action necessary to comply with a change
in applicable law, irrespective of the status of any Award as
vested or unvested, exercisable or unexercisable, at the time of
such change in applicable law.
11.3 CHANGES IN COMMON STOCK OR
ASSETS OF THE COMPANY, ACQUISITION OR LIQUIDATION OF THE COMPANY
AND OTHER CORPORATE EVENTS.
11.3.1 In the event that the Committee determines, in its
sole discretion, that any dividend or other distribution
(whether in the form of cash, Common Stock, other securities, or
other property), on account of a recapitalization,
reclassification, stock split, reverse stock split,
reorganization, merger, consolidation, split-up, spin-off,
combination, repurchase, liquidation, dissolution, or sale,
transfer, exchange or other disposition of all or substantially
all of the assets of the Company, or exchange of Common Stock or
other securities of the Company, issuance of warrants or other
rights to purchase Common Stock or other securities of the
Company, or other similar event, affects the Common Stock such
that an adjustment is appropriate in order to prevent
B-13
dilution or enlargement of the benefits or potential benefits
intended to be made available under the Plan, then the Committee
may, in such manner as it may deem equitable, adjust any or all
of the following:
11.3.1.1 the maximum number of
shares of Common Stock available for Awards;
11.3.1.2 the maximum number of
shares of Common Stock subject to the Plan;
11.3.1.3 the number and kind of
Company stock with respect to which an Award may be made under
the Plan;
11.3.1.4 the number and kind of
Company stock subject to an outstanding Award; and
11.3.1.5 the exercise price or
purchase price with respect to any Award.
11.3.2 In the event of any transaction or event described
in Section 11.3.1 or any unusual or nonrecurring
transactions or events affecting the Company, any Affiliate, or
the financial statements of the Company or any Affiliate, or of
changes in applicable laws, regulations, or accounting
principles, the Committee in its discretion is hereby authorized
to take any one or more of the following actions whenever the
Committee determines, in its sole discretion, that such action
is appropriate in order to prevent dilution or enlargement of
the benefits or potential benefits intended to be made available
under the Plan or with respect to any Award or right under this
Plan, to facilitate such transactions or events or to give
effect to such changes in laws, regulations or principles:
11.3.2.1 the Committee may provide, either by the terms of
the Award Agreement or by action taken prior to the occurrence
of such transaction or event and either automatically or upon
the Participants request, for (i) the purchase of any
such Award for the payment of an amount of cash equal to the
amount that could have been attained upon the exercise of such
Award or realization of the Participants rights had such
Award been currently exercisable, payable, fully vested or the
restrictions lapsed, or (ii) the replacement of such Award
with other rights or property selected by the Committee;
11.3.2.2 the Committee may provide in the terms of such
Award Agreement or by action taken prior to the occurrence of
such transaction or event that the Award cannot be exercised
after such event;
11.3.2.3 the Committee may provide, by the terms of such
Award or by action taken prior to the occurrence of such
transaction or event, that for a specified period of time prior
to such transaction or event, such Award shall be exercisable,
notwithstanding anything to the contrary in Section 4.6 or
the provisions of such Award;
11.3.2.4 the Committee may provide, by the terms of such
Award or by action taken prior to the occurrence of such
transaction or event, that upon such event, such Award be
assumed by the successor or survivor corporation, or a parent or
subsidiary thereof, or shall be substituted for by similar
Awards covering the stock of the successor or survivor
corporation, or a parent or subsidiary thereof, with appropriate
adjustments as to the number and kind of shares and prices;
11.3.2.5 the Committee may make adjustments in the number,
type and kind of shares of Common Stock subject to outstanding
Options, Restricted Common Stock, Restricted Stock Units,
Deferred Stock Units, SARs and Performance Units and in the
terms and conditions of (including the grant or exercise price),
and the criteria included in, outstanding Awards, and rights and
awards which may be granted in the future; and
11.3.2.6 the Committee may provide either by the terms of
a, Award of Restricted Common Stock or Restricted Stock Units or
by action taken prior to the occurrence of such event that, for
a specified period of time prior to such event, the restrictions
imposed under an Award Agreement upon some or all shares of the
Restricted Common Stock or the Restricted Stock Units may be
terminated, and some or all shares of such Restricted Common
Stock or some or all of such Restricted Stock Units may cease to
be subject to forfeiture under Section 6.5 or repurchase
under Section 6.6 after such event.
11.3.3 Subject to Section 11.7, the Committee may, in
its sole discretion, at the time of grant, include such further
provisions and limitations in any Award Agreement or
certificate, as it may deem appropriate and
B-14
in the best interests of the Company; provided, however, that no
such provisions or limitations shall be contrary to the terms of
the Participants Employment Agreement or the terms of this
Plan.
11.3.4 Notwithstanding the foregoing, in the event of a
transaction or event described in Sections 11.3.1 or any
unusual or nonrecurring transactions or events affecting the
Company, no action pursuant to this Section 11.3 shall be
taken that is specifically prohibited under applicable law, the
rules and regulations of any governing governmental agency or
national securities exchange, or the terms of the
Participants Employment Agreement.
11.4 CONTINUED EMPLOYMENT. Nothing
in this Plan or in any Award Agreement hereunder shall confer
upon any Participant any right to continue his employment,
consulting or similar relationship with the Company or an
Affiliate, whether as an Employee, Consultant, Director or
otherwise, or shall interfere with or restrict in any way the
rights of the Company or an Affiliate, which are hereby
expressly reserved, to discharge or terminate the relationship
with any Participant at any time for any reason whatsoever,
subject to the terms of any Employment Agreement entered into by
the Participant and the Company or Affiliate.
11.5 TAX WITHHOLDING. The Company
shall be entitled to require payment in cash or deduction from
other compensation payable to each Participant of any sums
required by federal, state or local tax law to be withheld with
respect to the issuance, vesting, exercise or lapse of any
restriction of any Option, Restricted Common Stock, Restricted
Stock Unit, Deferred Stock Unit, SAR or Performance Unit. The
Committee may, in its sole discretion and in satisfaction of the
foregoing requirement, allow such Participant to elect to have
the Company withhold shares of Common Stock otherwise issuable
under such Award (or allow the return of shares of Common Stock)
having a Fair Market Value equal to the sums required to be
withheld; provided, however, that any shares of Common Stock
withheld shall be no greater than an amount that does not exceed
the Participants minimum applicable withholding tax rate
for federal (including FICA), state and local tax liabilities.
11.6 FORFEITURE PROVISIONS.
Pursuant to its general authority to determine the terms and
conditions applicable to Awards, the Committee shall have the
right to provide, in the terms of such Award, or to require the
recipient to agree by separate written instrument, that
(i) any proceeds, gains or other economic benefit actually
or constructively received by the recipient upon any receipt or
resale of any Common Stock underlying such Award, must be paid
to the Company until such time the Company becomes publicly
traded, and (ii) the Award shall terminate and any
unexercised portion of such Award (whether or not vested) shall
be forfeited, if (a) a Termination of Employment occurs
prior to a specified date, or within a specified time period
following receipt or exercise of the Award, (b) the
recipient at any time, or during a specified time period,
engages in any activity in competition with the Company, or
which is inimical, contrary or harmful to the interests of the
Company, as further defined by the Committee or as specified in
the Participants Employment Agreement, or (c) the
Company terminates the Employee with or without Cause.
11.7 LIMITATIONS APPLICABLE TO
SECTION 16 PERSONS AND PERFORMANCE-BASED COMPENSATION.
Notwithstanding any other provision of this Plan, any Option,
Restricted Common Stock, Restricted Stock Unit, Deferred Stock
Unit, SARs, or Performance Units granted or awarded to any
individual who is then subject to Section 16 of the
Exchange Act shall be subject to any additional limitations set
forth in any applicable exemptive rule under Section 16 of
the Exchange Act (including any amendment to Rule 16b-3 of
the Exchange Act). To the extent permitted by applicable law,
Options granted or awarded hereunder shall be deemed amended to
the extent necessary to conform to such applicable exemptive
rule. Furthermore, notwithstanding any other provision of this
Plan to the contrary, any Award which is granted to a
Section 162(m) Participant and is intended to qualify as
performance-based compensation as described in
Section 162(m)(4)(C) of the Code shall be subject to any
additional limitations set forth in Section 162(m) of the
Code (including any amendment to Section 162(m) of the
Code) or any regulations or rulings issued thereunder that are
requirements for qualification as performance-based compensation
as described in Section 162(m)(4)(C) of the Code, and this
Plan shall be deemed amended to the extent necessary to conform
to such requirements.
B-15
11.8 RESTRICTIONS.
11.8.1 Except as otherwise provided for in the Award
Agreement, upon any Termination of Employment, for a one year
period thereafter, the Company shall have the right, but not the
obligation, to purchase all vested shares of Common Stock
awarded hereunder or acquired pursuant to an Award, for their
Fair Market Value at the time of purchase by the Company. These
rights shall be in addition to the right of first refusal
pursuant to Section 11.8.2; provided, however, that in the
event the Company decides not to exercise its rights pursuant to
Section 11.8.2, the provisions of this Section 11.8.1
shall cease to apply with respect to those shares of Common
Stock that were offered to the Company and sold in accordance
with the provisions of Section 11.8.2.
11.8.2 Except as otherwise provided for in the Award
Agreement, if an individual desires and is permitted to sell,
encumber, or otherwise dispose of shares of Common Stock awarded
hereunder or acquired pursuant to an Award, the individual shall
first offer the shares to the Company by giving the Company
written notice disclosing: (i) the name of the proposed
transferee of the Common Stock, (ii) the certificate number
and number of shares of Common Stock proposed to be transferred
or encumbered, (iii) the proposed price, (iv) all
other terms of the proposed transfer, and (v) a written
copy of the proposed offer. Within 60 days after receipt of
such notice, the Company shall have the option to purchase all
or part of such Common Stock at the same price and on the same
terms as contained in such notice (the Company Option
Period). In the event the Company does not exercise the
option to purchase the Common Stock, as provided above, the
individual shall have the right to sell, encumber or otherwise
dispose of his shares of Common Stock on the terms of the
transfer set forth in the written notice to the Company,
provided such transfer is effected within 30 days after the
expiration of the Company Option Period. If the transfer is not
effected within such period, the Company must again be given an
option to purchase, as provided above.
11.8.3 On and after the date a class of the Companys
securities are registered under Section 12(b) or 12(g) of
the Exchange Act, the Company shall have no further right to
purchase shares of Common Stock under this Section 11.8,
and its limitations shall be null and void.
11.8.4 Notwithstanding the foregoing, the Committee may
require that a Participant execute any other documents it deems
necessary or desirable with respect to any Common Stock
distributed or purchased pursuant to this Plan.
11.9 RESTRICTIVE LEGEND. All of the
shares of Common Stock now outstanding or hereafter issued
and/or owned shall be held and transferred subject to the terms
of the restrictions herein contained and every certificate
representing a share of Common Stock shall contain the following
legend: These shares are held subject to the terms of the
2004 Equity Incentive Plan (the Plan) and such
shares may only be transferred in accordance with the terms
thereof. A copy of the Plan is available at the office of the
Company.
11.10 EFFECT OF PLAN UPON OPTION
AND COMPENSATION PLANS. The adoption of this Plan shall not
affect any other compensation or incentive plans in effect for
the Company. Nothing in this Plan shall be construed to limit
the right of the Company (i) to establish any other forms
of incentives or compensation for Employees, Consultants or
Directors, or (ii) to grant or assume options or other
rights otherwise than under this Plan in connection with any
proper corporate purpose including but not by way of limitation,
the grant or assumption of options in connection with the
acquisition by purchase, lease, merger, consolidation or
otherwise, of the business, stock or assets of any corporation,
partnership, limited liability company, firm or association.
11.11 COMPLIANCE WITH LAWS. This
Plan, the granting and vesting of Awards under this Plan and the
issuance and delivery of shares of Common Stock and the payment
of money under this Plan or under Awards awarded hereunder are
subject to compliance with all applicable federal and state
laws, rules and regulations (including but not limited to state
and federal securities law and federal margin requirements) and
to such approvals by any listing, regulatory or governmental
authority as may, in the opinion of counsel for the Company, be
necessary or advisable in connection therewith. Any securities
delivered under this Plan shall be subject to such restrictions,
and the person acquiring such securities shall, if requested by
the Company, provide such assurances and representations to the
Company as the Company may deem necessary or
B-16
desirable to assure compliance with all applicable legal
requirements. To the extent permitted by applicable law, the
Plan shall be deemed amended to the extent necessary to conform
to such laws, rules and regulations.
11.12 TITLES. Titles are provided
herein for convenience only and are not to serve as a basis for
interpretation or construction of this Plan.
11.13 GOVERNING LAW. This Plan and
any agreements hereunder shall be administered, interpreted and
enforced under the laws of the State of Alabama, without regard
to conflicts of laws thereof.
IN WITNESS WHEREOF, the undersigned has caused this amended and
restated Plan to be executed on behalf of the Company as of
October , 2005.
|
|
|
MEDICAL PROPERTIES TRUST, INC. |
|
|
|
|
|
Chairman of the Board, President and |
B-17
Medical
Properties Trust, Inc. 1000 Urban Center Drive, Suite 501,
Birmingham, Alabama 35242
205-969-3755 www.medicalpropertiestrust.com
September 13, 2005
Dear Stockholder:
It is a great pleasure to have this opportunity to provide you with the Proxy
Statement for our 2005 Annual Meeting of Stockholders. The Proxy Statement
provides you with information relating to the business to be conducted at our
annual meeting on October 12, 2005.
YOUR VOTE IS IMPORTANT!
Please submit your proxy by completing, signing, dating, and returning your
proxy card in the accompanying envelope.
Thank you for your continued interest in, and ownership of, Medical Properties
Trust, Inc.
|
|
|
|
|
|
Sincerely,
|
|
|
/s/ Edward K. Aldag, Jr.
|
|
|
Edward K. Aldag, Jr. |
|
|
Chairman of the Board,
Chief Executive Officer and President |
|
|
|
PROXY
MEDICAL PROPERTIES TRUST, INC.
2005 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON OCTOBER 12, 2005
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The 2005 Annual Meeting of Stockholders of Medical Properties Trust, Inc. (the
Company) will be held at The Summit Club, 1901 6th Avenue North, Birmingham,
Alabama, on October 12, 2005, beginning at 10:00 a.m. Central Time. The
undersigned hereby acknowledges receipt of the combined Notice of 2005 Annual
Meeting of Stockholders and Proxy Statement dated September 13, 2005,
accompanying this proxy, to which reference is hereby made for further
information regarding the meeting and the matters to be considered and voted on
by the stockholders at the meeting.
The undersigned hereby appoints Edward K. Aldag, Jr. and R. Steven Hamner, and
each of them, attorneys and agents, with full power of substitution, to vote, as
the undersigneds proxy, all the shares of common stock of the Company owned of
record by the undersigned as of the record date and otherwise to act on behalf
of the undersigned at the meeting and any adjournment thereof, in accordance
with the instructions set forth herein and with discretionary authority with
respect to any other business, not known or determined at the time of the
solicitation of this proxy, that properly comes before such meeting or any
adjournment thereof.
The undersigned hereby revokes any proxy heretofore given and directs said
attorneys and agents to vote or act as indicated on the reverse side hereof.
(Continued and to be signed on the reverse side)
ANNUAL MEETING OF STOCKHOLDERS OF
MEDICAL PROPERTIES TRUST, INC.
October 12, 2005
Please date, sign and mail
your proxy card in the
envelope provided as soon
as possible.
ê Please detach along perforated line and mail in the envelope provided. ê
THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE "FOR" THE PROPOSALS.
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x
1. |
|
To elect eight directors. |
|
|
|
|
|
|
|
|
|
|
|
NOMINEES: |
o |
|
FOR ALL NOMINEES |
|
|
|
m
Edward K. Aldag, Jr.
m Virginia A. Clarke |
o |
|
WITHHOLD AUTHORITY FOR ALL NOMINEES |
|
|
|
m G. Steven Dawson
m Bryan L. Goolsby
m R. Steven Hamner |
o |
|
FOR ALL EXCEPT (See instructions below)
|
|
|
|
m
Robert E. Holmes, Ph.D.
m William G. McKenzie
m L. Glenn Orr, Jr.
|
|
|
|
|
|
|
INSTRUCTION:
|
|
To withhold authority to vote for
any individual nominee(s),
mark FOR ALL EXCEPT
and fill in the circle next to each nominee you wish to
withhold, as shown here:
l |
|
|
|
|
|
|
To change the address on your account, please check the box at right and
indicate your new address in the address space above. Please note that
changes to the registered name(s) on the account may not be submitted via
this method.
|
|
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
FOR |
|
AGAINST |
|
ABSTAIN |
2. |
|
To approve an amendment to the Amended and Restated Medical Properties
Trust, Inc. 2004 Equity Incentive Plan as described in the Proxy Statement. |
|
o |
|
o |
|
o |
|
|
|
|
|
|
|
|
|
3. |
|
To approve amendments to the Companys Charter related to transfers or
ownership restrictions on the Companys common stock as described in the
Proxy Statement.
|
|
o |
|
o |
|
o |
|
|
|
|
|
|
|
|
|
With respect to any other item of business that properly comes before the meeting,
the proxy holders are authorized to vote the undersigneds shares in accordance
with their best judgment. |
|
|
|
|
|
|
|
|
|
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF THE
COMPANY AND WILL BE VOTED IN ACCORDANCE WITH THE UNDERSIGNEDS
INSTRUCTIONS SET FORTH HEREIN. IF NO INSTRUCTIONS ARE PROVIDED,
THIS PROXY WILL BE VOTED FOR EACH OF THE PROPOSALS DESCRIBED
ABOVE. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature
of Stockholder
|
|
|
|
Date:
|
|
|
|
Signature of Stockholder
|
|
|
|
Date:
|
|
|
|
|
|
Note: |
|
Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When
signing as executor, administrator, attorney, trustee or guardian, please give full
title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such.
If signer is a partnership, please sign in partnership name by authorized person. |